Introduction {#s1}
============

The *T-box* gene family encodes transcription factors that play critical roles during embryonic development, organogenesis, and tissue homeostasis. Mutations in *TBX* genes in humans cause multiple developmental dysmorphic syndromes and disease predispositions ([@bib64]; [@bib82]). Heterozygous mutation of *TBX3* causes Ulnar-mammary syndrome (UMS), initially described as a constellation of congenital limb defects, apocrine and mammary gland hypoplasia, and genital abnormalities ([@bib69]). Recently, heart and conduction system defects have also been described in mice and humans with abnormal *Tbx3* (mice) and *TBX3* (humans) function ([@bib3]; [@bib21]; [@bib49]; [@bib58]; [@bib59]). Germline deletion of *Tbx3* in mice results in embryonic lethality with heart, limb, and mammary defects ([@bib15]; [@bib21]; [@bib22]). Tbx3 also regulates pluripotency and cell fate in early development ([@bib11]; [@bib25]; [@bib37]; [@bib66]; [@bib97]).

TBX3 transcriptional repression controls expression of cell proliferation and senescence factors ([@bib7]; [@bib41]); abnormal *TBX3* expression occurs in multiple cancers ([@bib52]; [@bib55]; [@bib71]). TBX3 also regulates splicing and RNA metabolism ([@bib42]). Although these studies highlight the important pleiotropic molecular functions of TBX3, little is known about the core pathways it regulates in developing structures that require its function, such as the developing limb.

UMS limb phenotypes are variable ranging in severity from hypoplasia of digit 5 to complete absence of forearm and hand (OMIM \#181450). Mouse *Tbx3^tm1Pa/tm1Pa^* ([@bib15]) and *Tbx3^Δfl/Δfl^*([@bib22]) mutant forelimbs lack posterior digits and the ulna. Hindlimbs of *Tbx3^tm1Pa/tm1Pa^* and *Tbx3^Δfl/Δfl^*null mutants have only a single digit, but *Tbx3^Δfl/Δfl^*mutants also have pelvic defects ([@bib22]). Embryonic lethality of both types of mutants has prevented elucidation of Tbx3's limb-specific roles.

The Hedgehog pathway is a key regulator of limb development. Shh signaling in posterior mesenchyme promotes digit development and prevents processing of full length Gli3 (Gli3FL) to its repressor form, Gli3R, which constrains digit number ([@bib50]). The balance of Gli transcriptional activation and repression is critical for proper digit number and patterning ([@bib9]; [@bib31]; [@bib50]; [@bib87]; [@bib91]; [@bib94]; [@bib107]). In mammals, the limited, partial proteolytic processing of Gli3FL to Gli3R requires functional primary cilia, the ciliary protein Kif7 ([@bib24]; [@bib51]), as well as balanced activity of Sufu and the ubiquitin ligase adaptors βTrCP and Spop ([@bib10]; [@bib92]; [@bib95]; [@bib98])

In this study, conditional ablation of *Tbx3* reveals discrete roles for Tbx3 during limb initiation and compartment-specific functions during later limb development to regulate digit number. We discovered a novel molecular function of Tbx3 in the primary cilia where it interacts directly with Kif7 and is in a complex with Gli3. Loss of Tbx3 decreases Kif7-Sufu interactions, resulting in excess Gli3 proteolysis and decreased levels of both Gli3FL and Gli3R. The resulting preaxial polydactyly phenocopies limb defects seen in *Gli3* null heterozygotes and in mutants with abnormal structure or function of the primary cilia ([@bib12]; [@bib17]; [@bib24]; [@bib28]; [@bib48]; [@bib51]; [@bib68]; [@bib73]). Our findings reveal a novel mechanism where Tbx3 in the anterior mesenchyme is required for proper function of the Kif7/Sufu complex that regulates Gli3 stability and processing.

Results {#s2}
=======

Loss of Tbx3 in the limb bud mesenchyme results in preaxial polydactyly and postaxial oligodactyly {#s2-1}
--------------------------------------------------------------------------------------------------

*Tbx3* is expressed in discrete anterior and posterior mesenchymal domains in the limb buds from embryonic day (E) 9.5 ([Figure 1A,C,E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). To assess the role of these domains during limb development, we generated conditional mutants using our *Tbx3^flox^* allele ([@bib21]; [@bib22]) and the *Prx1Cre* transgene ([@bib53]) (genotype *Tbx3^flox/flox^;Prx1Cre*, henceforth referred to in the text as *Tbx3;PrxCre* mutants). This driver initiates Cre activity at \~14-somite stage (ss) in the forelimb-forming region of the lateral plate mesoderm (LPM) ([@bib27]). Its activity in the hindlimb is irregular, so our analysis focuses on the forelimb. In situ hybridization and immunohistochemistry confirm complete ablation of *Tbx3* mRNA and protein in *Tbx3;PrxCre* mutant forelimb mesenchyme by E9.5 ([Figure 1B--F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Expression in the apical ectodermal ridge (AER) is preserved ([Figure 1B,D,F](#fig1){ref-type="fig"}). We previously reported the specificity of the custom anti-Tbx3 antibody used here and loss of limb mesenchymal protein production in *Tbx3;PrxCre* mutant forelimbs ([@bib21]; [@bib22]).10.7554/eLife.07897.003Figure 1.Tbx3 regulates anterior and posterior digit development.(**A**) *Tbx3* expression assayed by mRNA in situ hybridization in E9.5 forelimb bud (black line from a-p shows anterior-posterior axis). Red arrow points to *Tbx3* expression in apical ectodermal ridge (AER). Red ellipse encloses posterior mesenchymal expression domain. (**B**) *Tbx3* transcripts are absent in the limb bud mesenchyme of E9.5 *Tbx3^fl/fl^;PrxCre* mutants. *Tbx3* expression persists in the AER (red arrow) and adjacent posterior-lateral body wall (black arrowhead). (**C**, **D**) As in A and B except limb buds are E10.5. Red ellipses enclose anterior and posterior mesenchymal expression domains which are Tbx3 negative in the mutants. Red arrows highlight expression in AER. (**E**, **F**) Tbx3 immunohistochemistry on sectioned E10.5 limb. Tbx3 protein is lost in mesenchyme of *Tbx3^fl/fl^;PrxCre* mutants (F, red ellipses) but AER staining persists as expected (white arrowhead). Please see also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. (**G--J**) Skeleton preparations reveal preaxial polysyndactyly (duplicated/fused digit 1,red bracket, **H**, **H', J**) and postaxial oligodactyly (absent digit 5, red arrows in H' and J) in *Tbx3^fl/fl^;PrxCre* mutants at E15.5 (**H**, **H'**) and E19.5 (**J**). Note delayed ossification of the humerus (H, black arrowhead), loss of deltoid tuberosity (**J**, black arrowhead) and short, bowed ulna (**J**, black arrow) in mutant. s, scapula; h, humerus; oc, ossification center; dt, deltoid tuberosity r, radius; u, ulna; digits numbered 1--5 (**K**--**N**) *Sox9* mRNA expression shows evolving skeletal defects are already evident in *Tbx3^fl/fl^;PrxCre* mutants at E10.5- E11.5. Digit condensations are numbered. Bracket in L shows broadening of digit 1 forming region; red arrows highlight indentation in digit 5 forming region (**L**, **N**) and absence of Sox9 digit 5 condensation (**N**).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.003](10.7554/eLife.07897.003)10.7554/eLife.07897.004Figure 1---figure supplement 1.Ablation of Tbx3 with PrxCre eliminates anterior and posterior mesenchymal protein production.From Frank et al., PLoSOne 2013, with permission. Confocal micrographs of sectioned E10.0 forelimb buds after fluorescent immunohistochemical detection of Tbx3 using custom antibody to its C-terminus. (**C1--C4**) Tbx3+/+ limb bud. C1) Merged color view of DAPI and FITC channels at 10X magnification. (**C2**--**C4**) 60X magnification of white boxed region in **C1**. (**C2**) DAPI channel showing DNA immunoreactivity. (**C3**) FITC channel showing Tbx3 immunoreactivity. (**C4**) Merged view. (**D1**--**C4**) *Tbx3^fl/fl^;PrxCre* limb bud. (**D1**) Merged color view of DAPI and FITC channels at low magnification. (**D2**--**C4**) 60X magnification of white boxed region in D1. (**D2**) DAPI channel showing DNA immunoreactivity. (**D3**) FITC channel showing lack of Tbx3 immunoreactivity in nucleus and cytoplasm. (**D4**) Merged view.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.004](10.7554/eLife.07897.004)10.7554/eLife.07897.005Figure 1---figure supplement 2.Increased severity of limb phenotypes in *Tbx3* null mutants (*Tbx3^Δfl/Δfl^*) compared to *Tbx3;PrxCre* is independent of Tbx3 in the AER.(**A**--**D**) Skeleton preparations comparing control (A: Tbx3*^Δfl/+^*, C:Tbx3*^fl/fl^), Tbx3^Δfl/Δfl^*(B, null), Tbx3*^fl/fl^* and *Tbx3^fl/fl^;PrxCre* (D, conditional mutant) forelimbs. Note single digit, absent ulna, and shortened humerus in *Tbx3^Δfl/Δfl^*mutant (**B**) compared to preaxial polysyndactyly and absent digit 5 in *Tbx3;PrxCre* mutants (**D**). s, scapula; h, humerus; r, radius; u, ulna; digits are numbered; red arrowhead highlights loss of digit 5. (**E**, **F**) X-gal stained E10.0 (**E**) and E11.5 (**F**) *Rosa^LacZ/+^;Fgf8^mcm/+^*embryos after the administration of tamoxifen at E8.5; black arrow indicates staining indicative of previous Cre activity in the AER. (**G**--**J**) mRNA in situ for *Tbx3* expression shows the absence of signal in the AER of *Tbx3^fl/fl^;Fgf8^mcm/mcm^*E9.5 and E10.5 mutants (**H**, **J**, respectively) compared to controls (**G**, **I**). White arrows point to AER in **G**--**J**; note persistent mesenchymal *Tbx3* expression as expected. (**K**--**N**) Skeleton preparations comparing E15.5 control (**K**,**M**), and *Tbx3 ^fl/fl^;Fgf8^mcm/mcm^* (**L**) and *Tbx3^fl/fl^;RarCre* (**N**) mutants. Forelimbs of *Tbx3 ^fl/fl^;Fgf8^mcm/mcm^* mutants are normal (**L**), while defects in *Tbx3^fl/fl^;RarCre* (**N**) phenocopy those of *Tbx3;PrxCre* mutants (compare panel N to D and also to [Figure 1](#fig1){ref-type="fig"}, panel **H**).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.005](10.7554/eLife.07897.005)

Unlike mid-gestational lethality seen in constitutive *Tbx3* mutants ([@bib15]; [@bib22]), *Tbx3;PrxCre* mutants survive to adulthood with forelimb defects ([Video 1](#media1){ref-type="other"}): 100% have bilateral preaxial polysyndactyly of digit 1 (called PPD1 in humans \[[@bib56]\]), and 70% lack digit 5 ([Figure 1G--J](#fig1){ref-type="fig"}). Loss of digit 5 was bilateral in 6/18 and in the remaining, only affected the left forelimb ([Table 1](#tbl1){ref-type="table"}). This is not due to asymmetric activity of PrxCre because it is also observed in *Tbx3^Δfl/Δfl^*mutants (*^Δfl^* = recombined floxed conditional allele) where no Cre activity is involved ([@bib22]). Delayed ossification of the humerus ([Figure 1H](#fig1){ref-type="fig"}) and loss of the deltoid tuberosity ([Figure 1J](#fig1){ref-type="fig"}) were also observed. Abnormal limb bud morphology is evident by E10.5 ([Figure 1L](#fig1){ref-type="fig"}) and evolving skeletal defects at E11.5 by the altered pattern of *Sox9* expression ([Figure 1N](#fig1){ref-type="fig"}).10.7554/eLife.07897.006Table 1.Increased severity of left limb defects in Tbx3;PrxCre mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.006](10.7554/eLife.07897.006)Skeletal phenotypes: E13.5-adultLoss of digit 5BilateralLeft onlyRight only*Tbx3 ^fl/+\ or\ fl/fl^*000*Tbx3^fl/fl^;PrxCre*6120Molecular phenotypes: gene expressionExpression pattern or levelLeft = RightLeft \>RightRight \> Left*Tbx3 ^fl/+\ or\ f/fl^*controlcontrolcontrol*Tbx3^fl/fl^;PrxCre*19301Video 1.Adult Tbx3;PrxCre mutant mouse is healthy and mobile despite forelimb deformities.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.007](10.7554/eLife.07897.007)10.7554/eLife.07897.007

*Tbx3;PrxCre* mutant limb defects are less severe than constitutive nulls {#s2-2}
-------------------------------------------------------------------------

Germline *Tbx3* null mutants (genotype *Tbx3^Δfl/Δfl^*) have more severe forelimb defects than *Tbx3;PrxCre* conditional mutants: of the few *Tbx3^Δfl/Δfl^* mutants that survive to E13.5, 100% have agenesis of the ulna and digits 3--5 ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). Their hindlimbs have a single digit and no fibula ([@bib22]), phenocopying *Shh* and *Hand2* null mutants ([@bib23]). Variable timing of *Tbx3* loss of function by *PrxCre* may account for the disparate forelimb phenotypes of *Tbx3^Δfl/Δfl^*and *Tbx3;PrxCre* mutants, however, our skeletal data and phenotypes of *Tbx3^Δfl/fl^;PrxCre* mutants indicate that such variability manifests as incomplete penetrance of the ulnar and digit 5 defects ([Figure 1 H, H\',J](#fig1){ref-type="fig"}, and Colesanto et al., in preparation).

The AER is a critical signaling center, and *Tbx3* expression is preserved in the AER of *Tbx3;PrxCre* mutants ([Figure 1B,D,F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [@bib22]). We tested whether AER Tbx3 has a required function using two Cre drivers: *RarbCre* (active in AER and mesenchyme from E9.0 \[[@bib63]\]), and a novel *Fgf8^mcm^* allele, which produces tamoxifen-inducible Cre in *Fgf8* expression domains (Moon et al., in preparation). Tamoxifen induction at E8.5 induces robust Cre activity in the AER in RosaLacZ/+;*Fgf8^mcm/+^* embryos ([Figure 1---figure supplement 2E,F](#fig1s2){ref-type="fig"}) and ablates *Tbx3* from forelimb AER by at least E9.5 ([Figure 1---figure supplement 2G--J](#fig1s2){ref-type="fig"}). *Tbx3^fl/fl^;Fgf8^mcm/mcm^*mutants have normal limbs ([Figure 1---figure supplement 2L](#fig1s2){ref-type="fig"}) and phenotypes of *Tbx3^fl/fl^;PrxCre* and *Tbx3^fl/fl^;RarbCre* are indistinguishable ([Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"} versus N). The results with both Cre drivers indicate that the severe phenotypes of *Tbx3^Δfl/Δfl^*mutants are not due to a required function of *Tbx3* in the AER.

Tbx3 is required for normal limb bud initiation and *Tbx5* expression in the LPM {#s2-3}
--------------------------------------------------------------------------------

We next tested whether discrepant forelimb phenotypes in *Tbx3^Δfl/Δfl^* and *Tbx3;PrxCre* mutants reflect a role for *Tbx3* in an earlier expression domain than affected by *RarbCre* or *PrxCre*. Limb initiation in the LPM requires *Tbx5* expression in the prospective forelimb territory as early as the 8ss ([@bib61]), upstream of *Hand2* ([@bib1]). *Tbx3* is expressed in the LPM from E7.5 ([Figure 2A--C](#fig2){ref-type="fig"}'). Lineage tracing with a novel *Tbx3^mcm^*allele (Thomas et al., in preparation) revealed that *Tbx3*-expressing progenitors in the LPM at E8-8.5 give rise to most E10 forelimb mesenchyme in *Tbx3^mcm/+^;Rosa^LacZ/+^* embryos ([Figure 2D](#fig2){ref-type="fig"}). Consistent with a role for Tbx3 in limb initiation, *Tbx3^Δfl/Δfl^*mutants have decreased LPM expression of *Tbx5* ([Figure 2E,F](#fig2){ref-type="fig"}), visible defects in forelimb initiation and early limb bud morphology ([Figure 2G,H](#fig2){ref-type="fig"}), and disrupted expression of *Hand2* ([Figure 2I,J](#fig2){ref-type="fig"}). In contrast, early stage *Tbx5* expression and limb bud initiation are unaffected in *Tbx3;PrxCre* mutants ([Figure 2---figure supplement 1B,B\'](#fig2s1){ref-type="fig"})10.7554/eLife.07897.008Figure 2.Tbx3 is required for normal limb bud initiation.(**A**, **B**) *Tbx3* expression at E7.5 (**A**) and E8.5 (**B**). Anterior on left (**A**), posterior on right (P). NM (black arrow) indicates nascent mesoderm exiting primitive streak in panel **A**. (**C**, **C'**) *Tbx3* expression in the LPM (black arrow) of sectioned E8.5 embryo. Plane of section indicated by line in B. Panel D is magnification of red-boxed area in **C**. (**D**) X-gal stained E10.0 *Tbx3^MCM/+^; Rosa ^LacZ/+^* embryo after Cre induction at E8.5. FL, forelimb; HL, hindlimb. (**E**, **F**) 21 somite stage (ss) embryos assayed for *Tbx5* mRNA. White arrows denote forelimb bud. Left sided view. (**G**, **H**) Dorsal view of budding forelimbs of 24 ss embryo forelimbs (neural tube stained for *Shh* expression). Note abnormal shape and size of *Tbx3^Δfl/Δfl^*mutant forelimb buds indicative of disrupted initiation; white brackets are of equal size in both panels. (**I**, **J**) 22 ss embryos assayed for *Hand2* expression. Black arrows denote emerging forelimb bud.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.008](10.7554/eLife.07897.008)10.7554/eLife.07897.009Figure 2---figure supplement 1.Early *Tbx5* expression is normal in *Tbx3^fl/fl^;PrxCre* mutants.(**A--B'**) In situ hybridization for *Tbx5* mRNA on E9.5 control (**A**, **A'**) embryo versus *Tbx3;PrxCre* mutant (**B**, **B'**). Left sided views in A and B and dorsal views of dissected torsos with forelimbs in **A'**, **B'**. *Tbx5* expression and limb initiation are normal after conditional loss of Tbx3 in the limb bud mesenchyme. (**C**--**D'**) In situ hybridization for *Hand2* mRNA on E9.5 control (**A**, **A'**) embryo versus *Tbx3;PrxCre* mutant (**B**, **B'**). Left- sided views in C and D and dorsal views of dissected limbs in **C'**, **D'**. *Hand2* expression is affected by conditional loss of Tbx3 in limb bud mesenchyme, but not as severely as in *Tbx3^Δfl/Δfl^* mutants shown in [Figure 2J](#fig2){ref-type="fig"}. Boxed area in D encloses forelimb forming region shown from dorsal view in **D'**.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.009](10.7554/eLife.07897.009)

TBX3 positively regulates posterior digit development via the Hand2/Shh pathway in posterior mesenchyme {#s2-4}
-------------------------------------------------------------------------------------------------------

Our data reveal required functions for Tbx3 in limb initiation (demonstrated by *Tbx3^Δfl/Δfl^*mutants) and in later limb bud morphogenesis (demonstrated by *Tbx3;PrxCre* mutants). Most *Tbx3;PrxCre* mutants lack digit 5, whose specification and formation depend on \'early phase\' Shh signaling beginning at E9.5 ([@bib26]; [@bib80]; [@bib104]; [@bib105]). Hand2 protein is required to activate *Shh* expression in the limb bud ([@bib8]; [@bib23]). We found that *Hand2* transcripts are reduced in E9.5 and E10.5 *Tbx3;PrxCre* mutant forelimb buds ([Figure 2---figure supplement 1D,D\'](#fig2s1){ref-type="fig"}; [Figure 3A, A\',F](#fig3){ref-type="fig"}) as is *Shh* expression ([Figure 3B,B\',F](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Expression of two targets and effectors of Shh signaling, *Ptch1* and *Grem1*, is also markedly reduced ([Figure 3C\',E\'](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). *Tbx3* expression in posterior limb mesoderm begins earlier than in the anterior compartment ([Figure 1A,C](#fig1){ref-type="fig"}) and is required for normal *Hand2* in posterior mesoderm ([Figure 3A](#fig3){ref-type="fig"}, [Figure 2J](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}') ([@bib75]). Thus, intact *Tbx5* expression in *Tbx3;PrxCre* E9.5 forelimbs ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}') indicates that post-initiation, Tbx3 functions downstream of Tbx5 and upstream of *Hand2*.10.7554/eLife.07897.010Figure 3.Loss of mesenchymal Tbx3 disrupts Shh signaling in the posterior limb bud and decreases Gli3 protein stability.(**A**--**E'**) In situ hybridization of control and mutant forelimb buds with probes and at embryonic stages as labeled. (**F**) qPCR of E10.75 (36-39ss) limb buds for transcripts listed confirms findings by detected by in situ. (**G**--**I**') In situ hybridization for *Zic3, Epha3* and *Hoxd13* transcripts in forelimb buds of *Tbx3 ^fl/+^*controls (**K**--**M**) and *Tbx3;PrxCre* mutants (**G'**--**I'**) at ages noted on panels. J) qPCR assay of *Zic3, Epha3, Hoxd13* transcript levels confirms findings detected by in situ. (**K**--**L'**) Representative images of E10.5 forelimb buds stained for DAPI (blue), pHH3 (green), TUNEL (red). K is *Tbx3* ^fl/+^ control and K' is digital zoom of posterior mesenchymal boxed area in K. Panel L is *Tbx3;PrxCre* mutant and L' is digital zoom of boxed area in L. This experiment is representative of data obtained from five biologic replicates. (**M**) Quantification of proliferating cells in anterior and posterior mesenchymal regions encompassing digit 1 and digit 5 progenitors from 20 control and 15 mutant sections. \*p=0.02. Control anterior limb (CA), *Tbx3;PrxCre* mutant anterior limb (MA), control posterior (CP), and mutant posterior (MP). (**N**--**O'**) Representative images of E11.5 whole mount forelimb buds stained for DAPI (blue) and pHH3 (green). N is *Tbx3* ^fl/+^ control and N' is digital zoom of boxed area. Panel O is *Tbx3;PrxCre* mutant and O' is digital zoom of boxed area in O. Note decreased pHH3+ cells in mutants, particularly cells in prophase and anaphase, which have the faint and speckled patterns compared to the bright staining of highly condensed S-phase chromatin. (**P**) Quantification of proliferating cells in anterior and posterior mesenchymal regions encompassing digit 1 and digit 5 progenitors from 50 control and 44 mutant sections at E11.5. \*p\<0.1. Control anterior limb (CA), *Tbx3;PrxCre* mutant anterior limb (MA), control posterior (CP), and mutant posterior (MP).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.010](10.7554/eLife.07897.010)10.7554/eLife.07897.011Figure 3---figure supplement 1.Decreased Shh expression in E10.5 forelimb buds of Tbx3;PrxCre mutants.(**A**, **B**) Whole mount in situ hybridization for *Shh* transcripts on E10.5 embryos; left -sided views. (**C**, **D**) Dissected limbs from whole mount in situ hybridization for *Shh* transcripts on E11.0 embryos; dorsal views of left limb buds are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.011](10.7554/eLife.07897.011)10.7554/eLife.07897.012Figure 3---figure supplement 2.No evidence of ectopic hedgehog pathway activity in Tbx3;PrxCre mutant forelimbs.(**A**, **B**) In situ hybridization for *Ptch1* at E11.5 in control (**A**) versus *Tbx3;PrxCre* mutant (**B**) limb buds. *Ptch1* expression is decreased in posterior mesenchyme, consistent with results in [Figure 3](#fig3){ref-type="fig"}. There is no ectopic *Ptch1* signal in anterior mesenchyme. Note decreased size of *Ptch1* negative zone in posterior mesenchyme (white ellipses), consistent with loss of digit 5 progenitors which are unresponsive to Shh signaling at this stage ([@bib79]) [@bib2]). a, anterior; p, posterior (**C**, **D**). In situ hybridization for *Grem1* at E11.5 reveals decreased expression throughout limb, consistent with qPCR and in situ results shown in [Figure 3](#fig3){ref-type="fig"} at E10.75.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.012](10.7554/eLife.07897.012)10.7554/eLife.07897.013Figure 3---figure supplement 3.Microdissection of E11 forelimb buds into anterior and posterior compartments for gene and protein expression analyses.(**A**) Intact left limb bud after in situ hybridization for *Tbx3* mRNA. Anterior (ant) at top, posterior (post) at bottom. (**B**, **C**) Microdissected anterior and posterior Tbx3+ compartments and list of example genes whose expression is confined to, or enriched in, each compartment.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.013](10.7554/eLife.07897.013)10.7554/eLife.07897.014Figure 3---figure supplement 4.qPCR of additional key transcripts in anterior and posterior forelimb compartments at E10.5--10.75 (36--39 somite stages).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.014](10.7554/eLife.07897.014)10.7554/eLife.07897.015Figure 3---figure supplement 5.*Fgf8* expression and downstream in *Tbx3;PrxCre* mutant forelimb buds.(**A--F**) In situ hybridization for the transcripts listed on panels at ages specified. (**A**, **B**) View of AER stained for *Fgf8*. (**C**--**F**) Dorsal view of left forelimb buds stained for *Erm (Etv5)* and *Pea3 (Etv4)* transcripts which are regulated by FGF signaling in the limb bud.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.015](10.7554/eLife.07897.015)

To obtain a more comprehensive view of the transcriptional consequences of loss of Tbx3 in limb bud mesenchyme, we assayed gene expression of E10.25 limb buds (32--34 somite stage) by microarray. *Shh* and other hedgehog pathway members and target genes ([@bib45]; [@bib72]; [@bib90]; [@bib57])([@bib46]) were present among the significantly dysregulated transcripts ([Supplementary file 1](#SD12-data){ref-type="supplementary-material"}) consistent with the previous report of decreased *Shh* expression in *Tbx3^tm1Pa/tm1Pa^* mutant limb buds ([@bib15]). In addition to decreased levels of Shh- activated transcripts (*Gli1, Hand2, Osr1, Dkk1, Tbx2, Cntfr, Pkdcc*), we noted increased *Rprm, Zic3, Hand1,* and *Gli3* transcripts and confirmed these with qPCR and in situ hybridization at E10.5--11 ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). The increase in expression of these putative targets of the Gli3 repressor ([@bib45]; [@bib72]; [@bib90]; [@bib57]) was intriguing as it suggested the possibility of alterations in both Gli3 activator and repressor function in *Tbx3;PrxCre* mutant forelimbs.

The transcriptional profiles of anterior and posterior limb mesenchyme are quite different: alterations in gene expression in either compartment in response to Tbx3 could mask some changes in the other if assayed simultaneously. Thus, we proceeded to microdissect anterior and posterior limb segments and assayed them independently using RNA-sequencing on 38--42 somite stage (\~E11; this later stage was needed in order to obtain sufficient RNA from accurately microdissected limb segments) wild type and *Tbx3;PrxCre* mutant forelimb buds ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). The resulting RNA-Seq data confirmed accurate dissection with the expected distribution of known compartment-specific transcripts ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"} and [Supplementary file 2](#SD13-data){ref-type="supplementary-material"}). *Shh, Fgf4* and anterior *Hoxd* family transcripts were over-represented in the posterior compartment, and *Alx* and *Pax* family members in the anterior.

Largely consistent with the previous microarray findings, we found evidence of aberrant cell differentiation/fate of posterior mesenchyme with downregulation of Shh-activated targets (*Osr1, Dkk1, Tbx2, Cntfr, Ptch2*, [Supplementary file 3](#SD14-data){ref-type="supplementary-material"}) that validated by qPCR ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). It is known that *Gli3* expression increases with decreased Shh activity ([@bib91]), as we see here ([Figure 3D', F](#fig3){ref-type="fig"}). Although decreased levels of *Hand2, Shh, Ptch1 and Grem1* are clearly evident by in situ and qPCR at this stage ([Figure 3](#fig3){ref-type="fig"} and [figure upplements](#fig3s1){ref-type="fig"}), they were not detected on the RNA-Seq analysis for unclear reasons.

Shh signaling is required for proliferation to ensure sufficient cell numbers to form the normal complement of digits, and loss of Shh results in an increase in the number of cells in G1 arrest ([@bib105]). Assay of cell proliferation in E10.5 and E11.5 limb buds using anti-phosphohistone H3 immunohistochemistry revealed that at E10.5 there was a statistically significant decrease in the fraction of proliferating cells in the posterior mesenchyme ([Figure 3K--M](#fig3){ref-type="fig"}). At E11.5, proliferation was significantly decreased in both the anterior and posterior mesenchyme, indicating a global reduction in the number of mitotic cells in mutants ([Figure 3N--P](#fig3){ref-type="fig"}). This suggests that 5th digit agenesis is attributable, at least in part, to decreased cell number, as opposed to decreased proliferation specifically in digit 5 progenitors. Assay for apoptosis using TUNEL showed normal levels of anterior AER cell death at E10.5, as we have previously reported in this region ([@bib63]) ([Figure 3K,L](#fig3){ref-type="fig"}).

Proliferation of limb mesenchyme depends on activity of FGF8 and FGF4 from the AER ([@bib5]; [@bib63]; [@bib84]) and integrity of this structure requires Shh activity in posterior mesenchyme ([@bib13]). Despite decreased *Shh* expression in *Tbx3;PrxCre* mutants, *Fgf4* transcripts were increased in posterior mesenchyme while decreased in anterior (detected by RNA-Seq, [Supplementary files 3](#SD14-data){ref-type="supplementary-material"},[4](#SD15-data){ref-type="supplementary-material"} and qPCR, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}), the latter consistent with an expanded digit 1 region. qPCR detected increased *Fgf8* expression in the posterior AER ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Despite these changes in transcript levels, there was no evidence of altered downstream FGF signaling as expression of *Etv4, Etv5, Dusp6* and *Sprys* was unchanged ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}, note these transcripts are not listed in [Supplementary files 3 or 4](#SD14-data){ref-type="supplementary-material"} because they did not meet criteria for differential expression). We conclude that despite the decrement in Shh pathway activity in posterior mesenchyme of *Tbx3;PrxCre* mutants, the level is sufficient to maintain ectodermal FGF signaling, consistent with preserved limb outgrowth.

Tbx3 stabilizes Gli3 protein in anterior limb mesenchyme {#s2-5}
--------------------------------------------------------

To understand the cause of the anterior PPD phenotype in *Tbx3;PrxCre* mutants, we pursued molecular mechanisms known to cause this defect in humans and mice: ectopic Hedgehog pathway activity ([@bib31]; [@bib32]; [@bib45]); decreased Gli3R activity ([@bib30]; [@bib65]; [@bib94]); and abnormal composition or function of the primary cilia ([@bib24]).

RNA-Seq analysis of control versus mutant anterior compartments ([Supplementary file 4](#SD15-data){ref-type="supplementary-material"}) showed no evidence of ectopic hedgehog activity in *Tbx3;PrxCre* mutants, and this was confirmed by in situ hybridization and qPCR for *Shh* and *Ptch1* ([Figure 3B--C\'](#fig3){ref-type="fig"}, [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}). Although *Gli3* transcripts were increased in mutant limb buds ([Figure 3D\',F](#fig3){ref-type="fig"}; [Supplementary file 1](#SD12-data){ref-type="supplementary-material"}), targets of Gli3R transcriptional repression such as *Zic3, Epha3, Hoxd13* ([@bib57]; [@bib90]) were overexpressed when assayed by microarray, RNA-Seq, qPCR and in situ hybridization ([Figure 3 G-J](#fig3){ref-type="fig"}, [Supplementary files 1](#SD12-data){ref-type="supplementary-material"},[3](#SD14-data){ref-type="supplementary-material"},[4](#SD15-data){ref-type="supplementary-material"}).

The discrepancy between *Gli3* RNA levels and increased expression of some repressor targets prompted examination of Gli3 protein levels. Gli3R constitutes the vast majority of Gli3 protein species in the anterior limb bud ([@bib91]) and [Figure 4A](#fig4){ref-type="fig"}). Gli3R protein was markedly decreased (7.4 fold on this representative immunoblot) with multiple bands of lower molecular weight than Gli3R present specifically in *Tbx3;PrxCre* mutant anterior mesenchyme (mutant anterior compartment: MA, [Figure 4A](#fig4){ref-type="fig"}, red box). Gli3FL was virtually undetectable in mutant anterior mesenchyme ([Figure 4A](#fig4){ref-type="fig"}'). This finding is not due to poor sample quality because it was reproducible (N=3), no degradation was present in simultaneously prepared posterior compartment lysates (mutant posterior, MP), and the β−tubulin control was intact. These findings indicate that Tbx3 is required for stability of Gli3FL and Gli3R proteins in the anterior limb mesenchyme, and are consistent with the PPD phenotype observed here and in other models of Gli3R deficiency ([@bib30]; [@bib65]; [@bib94]).10.7554/eLife.07897.016Figure 4.Loss of Tbx3 results in Gli3 protein instability and aberrant localization of Kif7 in limb bud cilia.(**A**) Representative immunoblot (N=3) blot of E10.75 forelimb bud lysates prepared from microdissected *Tbx3^fl/+^*control anterior limb (CA), *Tbx3;PrxCre* mutant anterior limb (MA), control posterior (CP), and mutant posterior (MP) probed for Gli3 and βtubulin loading control. Note decreased level of Gli3FL and Gli3R, and multiple bands of lower molecular weight than Gli3R in MA sample. Densitometry of Gli3R bands in red box in N revealed that in this representative experiment, the level of Gli3R was 7.4 fold decreased in mutant anterior relative to control anterior. (**A'**) Longer exposure of top of blot shown in panel A to examine Gli3FL band. The control (CA) Gli3FL band is 31 fold more intense than mutant (MA, virtually undetectable). (**B**) Immunoblot of lysates from E10.5 forelimb buds immunoprecipitated (IB) with antibodies listed at top and immunoblotted (IB) for Tbx3. Lane 5 shows that immunoprecipitation with anti-Kif7 antibody co-IPs Tbx3. (**C**) As in panel B, but assayed for Kif7. (**D**) Co-IP assay of Myc-tagged Tbx3 and Flag-tagged GFP overexpressed in HEK293 cells. IP was performed with antibodies listed at top and immunoblotted for Tbx3. Myc-tagged Tbx3 co-IPs with Flag-tagged Kif7. Input lane was 5 s exposure (5" exp) while other lanes were 15 s (15" exp). (**E**) As in **D**, but in this case, blot probed for Kif7; confirms interaction of tagged, overexpressed proteins. (**F**, **G**) Representative images of anterior mesenchyme in sectioned forelimbs of control (**F**, *Tbx3^fl/fl^*) and mutant (G, *Tbx3^fl/fl^;PrxCre*) E10.5 embryos stained for the ciliary marker Arl13b (red), Kif7 (green) and DAPI (DNA, blue). White arrowheads highlight cilia with multiple punctae or streak of ciliary Kif7 immunoreactivity (yellow) indicating translocation of Kif7 within the cilia. Please also see [Figure 5---source data 2](#SD3-data){ref-type="supplementary-material"} for z-stacks of additional Kif7 stained limb section. (**H**) Quantification of Kif7 staining pattern from multiple limb sections and three embryos of each genotype scored blinded to genotype. 10% fewer cilia have evidence of Kif7 translocation (multiple punctae or streak of Kif7 immunoreactivity) in *Tbx3^fl/fl^;PrxCre* mutants. N=1785 and 1792 cilia scored in controls and mutants, respectively. \* p\<0.001 There was no difference in the number of Kif7- cilia. Insets show digital zoom of cilia with representative pattern used for scoring. (**I**) Immunoblot assaying for Kif7 and b tubulin loading control in control anterior (CA), mutant anterior (MA), control posterior (CP) and mutant posterior (MP) e10.5 forelimb bud lysates. This is representative of four such experiments. (**J**) Western blot assaying for Sufu protein and b tubulin loading control in eE10.5 forelimb buds. Like *Kif7* mutants,*Tbx3;PrxCre* mutants have increased Sufu protein. Sufu is increased 1.8 fold when normalized to loading control in this representative immunoblot; N=4. K) Western blot assaying for Spop protein and actin loading control in E10.5 forelimb buds. Spop is increased 1.5 fold when normalized to loading control in this representative immunoblot; N=3. Both Sufu and Spop protein levels are increased in mutant forelimbs although their transcript levels are unchanged ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.016](10.7554/eLife.07897.016)10.7554/eLife.07897.017Figure 4---source data 1.CZI file containing z-stack of E10.5 sectioned limb shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.Kif7 is green, Arl13b red, DNA blue. Gli3 signal can be viewed if desired in the violet channel (channel 2). The entire z stack can be viewed using the free download of Zen software: <http://www.zeiss.com/microscopy/en_de/downloads/zen.html>.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.017](10.7554/eLife.07897.017)10.7554/eLife.07897.018Figure 4---figure supplement 1.Kif7 is also present in cytoplasm and nucleus.100 X confocal maximum image projection of E10.5 sectioned limb stained for Kif7 (green), Arl13b (red) and DNA (blue). Please also see [Figure 5---source data 2](#SD3-data){ref-type="supplementary-material"} for z-stack.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.018](10.7554/eLife.07897.018)10.7554/eLife.07897.019Figure 4---figure supplement 2.Anterior mesenchymal limb cilia are bigger in Tbx3;PrxCre mutants compared to controls.(**A**) Distribution of cilia volumes in control and mutant limb buds. (**B**) Average cilia volumes and 95% confidence intervals. (**C**) Average surface area to volume ratios over the range of cilia volumes measured. (**D**) Calculated of surface area and volume of both WT and mutant cilia fit the equation: Surface=8.01 X Volume^0.69^**DOI:** [http://dx.doi.org/10.7554/eLife.07897.019](10.7554/eLife.07897.019)

TBX3 interacts with Kif7 and is required for normal Kif7 trafficking {#s2-6}
--------------------------------------------------------------------

In an independent experiment to identify Tbx3 interacting partners, we performed Tbx3 co-immunoprecipitation (co-IP) on E10.5 mouse embryo lysates, followed by mass spectrometry ([@bib42]). Surprisingly, Kif7 was among the Tbx3 interacting proteins identified. Kif7 is a ciliary protein that modulates activity of the Hedgehog pathway ([@bib34]). It is required for proper formation of a \'cilium tip\' compartment that regulates Gli function ([@bib29]), and for the regulated, partial proteolytic processing of GliFL to Gli3R ([@bib10]; [@bib12]; [@bib17]; [@bib43]; [@bib77]). As in *Tbx3;PrxCre* and *Gli3^+/-^* mutants ([@bib30]), human and mouse *Kif7* mutants have PPD ([@bib12]; [@bib17]; [@bib73]).

Immunoprecipitation of protein lysates from E10.5 forelimb buds showed that Tbx3 co-immunoprecipitates (co-IPs) with Kif7, confirming interaction of Kif7 and Tbx3 in the developing limb ([Figure 4B](#fig4){ref-type="fig"}; specificity and efficiency of Kif7 IP in this experiment is shown in [Figure 4C](#fig4){ref-type="fig"}). We next tested whether these proteins directly interact by overexpressing Flag-tagged Kif7 and Myc-tagged Tbx3 in HEK293 cells and immunoprecipitating for either Flag or Myc, followed by immunoblotting for Tbx3 ([Figure 4D](#fig4){ref-type="fig"}) or Kif7 ([Figure 4E](#fig4){ref-type="fig"}). Both experiments confirmed direct interaction of the tagged proteins.

The interaction of Tbx3 with Kif7, and the shared PPD phenotypes of *Kif7* and *Tbx3;PrxCre* mutants, suggest that Tbx3 may be required for normal Kif7 function in the anterior limb bud, and that loss of Tbx3 may disrupt Gli3 stability and processing in part via a Kif7-dependent mechanism.

We examined Kif7 localization in E11 control and mutant forelimb buds, co-staining for the cilia marker Arl13b. Confocal fields spanning the anterior mesenchyme of controls and mutants were imaged and [Figure 4F and G](#fig4){ref-type="fig"} are representative 40X fields (a higher magnification image and confocal z-stack, which also show Kif7 in the cytoplasm and nucleus are shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}). Blinded to genotype, fields were scored for ciliary Kif7 immunoreactivity as a single puncta, multiple punctae/streak, or none (N=1785 and 1792 cilia scored in controls and mutants, respectively). In 16% of control cilia, Kif7 was detected in two punctae (presumed base and tip) or as a streak along the cilia, but this was only the case in 6% of mutant cilia ([Figure 4H](#fig4){ref-type="fig"}, p\<0.001). There was no significant difference in the number of Kif7+ cilia rather, there were more single puncta cilia in mutants than controls ([Figure 4H](#fig4){ref-type="fig"}, 84% vs 71%, p\<0.001). We did not detect any difference in the amount of Kif7 protein in control versus mutant limb bud compartments by western blot ([Figure 4I](#fig4){ref-type="fig"}, representative of four4 separate experiments). Levels of *Kif7* mRNA in the anterior limb mesenchyme were unaffected by loss of Tbx3 ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). There was a decrease in the transcripts posterior compartment but as shown, the protein level was unchanged.

One feature of *Kif7^-/-^*mutants is excess Sufu due to increased protein stability ([@bib33]). Transcript levels of *Sufu* were unchanged in mutant forelimbs ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}, no difference was detected by microarray or RNA-Seq). However, increased amounts of Sufu (and Spop) protein were present in mutant limb buds ([Figure 4J,K](#fig4){ref-type="fig"}; increased 1.5 fold in both cases).

Humans and mice with *Kif7* mutations have abnormally long cilia because Kif7 reduces the rate of microtubule growth in the ciliary axoneme ([@bib29]; [@bib73]). With 3D images obtained from 100X confocal z-stacks of Arl13b stained limb sections, we used the 3D object counter from ImageJ to calculate the volume and surface area to volume ratio to derive the length of cilia. Consistent with aberrant, but not absent, Kif7 function, we found that while the range of cilia volumes detected were the same between mutants and controls, the distribution was not: mutants have an increased fraction of larger cilia and an average volume 18% greater ([Figure 4---figure supplement 2A, B](#fig4s2){ref-type="fig"}; 475 and 575 cilia assayed in controls and mutants, respectively). Mutants and controls had superimposable surface area/volume ratios ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}), indicating that the shape of cilia was not different thus, the derived length was 6% greater in mutants.

Together, these findings indicate that loss of Tbx3 results in aberrant ciliary localization of Kif7 and are consistent with abnormal Kif7 function.

Tbx3 is present in primary cilia and translocates in response to Hedgehog pathway activity {#s2-7}
------------------------------------------------------------------------------------------

Kif7 and other proteins required for Gli3 processing and function are present in, or translocate to, primary cilia in response to Hedgehog pathway activity ([@bib24]; [@bib77]). Dual immunostaining for Tbx3 and Arl13b on whole mount optically sectioned E10.5 forelimbs shows that Tbx3 is present in control limb anterior mesenchymal cilia ([Figure 5 A-E](#fig5){ref-type="fig"}, [Figure 5---source data 1](#SD2-data){ref-type="supplementary-material"}). Specificity of Tbx3 staining was confirmed by loss of signal in mesenchymal cilia of *Tbx3;PrxCre* mutant limbs ([Figure 5F-J](#fig5){ref-type="fig"}, [Figure 5---source data 2](#SD3-data){ref-type="supplementary-material"}). The digital image overlap calculator in Zen software showed that 18/50 anterior mesenchymal cilia were Tbx3+ (36%, [Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Of note, no epithelial cilia were Tbx3+ in control limb epithelium, providing an internal negative control for the signal in mesenchymal cilia. This same calculation in *Tbx3;PrxCre* mutant anterior mesenchyme showed only 2/54 (\<4%) of mesenchymal cilia had background Tbx3 signal ([Figure 5---figure supplement 1, C, D](#fig5s1){ref-type="fig"}). These findings were reproduced with a commercially available anti-Tbx3 antibody (Abcam ab99302) which also showed Tbx3 ciliary staining on control limb mesenchymal cilia (24/87, 28%) that was virtually absent in *Tbx3* mutant limbs (2/52, \<4%; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).10.7554/eLife.07897.020Figure 5.Tbx3 localizes to the primary cilia in limb mesenchyme.(**A--D**, **F**--**I**) Confocal 100X single Z-plane immunofluorescence images from optically sectioned E10.5 control (top panels **A**--**D**) and *Tbx3;PrxCre* (**F**--**I**) anterior limb buds after immunostaining with: Hoechst (DNA, blue), C-terminal anti-Tbx3 antibody (green, [@bib22]), anti-Arl13b (red, cilia). Arrowheads demarcate Tbx3 colocalization with cilia marker. Panels E and J are further digital zooms of white boxed cells in D and I. The entire z-stacks containing these planes are in [Figure 5---source data 1](#SD2-data){ref-type="supplementary-material"},[2](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.020](10.7554/eLife.07897.020)10.7554/eLife.07897.021Figure 5---source data 1.Czi file of z-stack through the region of control anterior limb shown in [Figure 5A--E](#fig5){ref-type="fig"}.The entire z stack can be viewed using the free download of Zen software <http://www.zeiss.com/microscopy/en_de/downloads/zen.html>.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.021](10.7554/eLife.07897.021)10.7554/eLife.07897.022Figure 5---source data 2.Czi file of z-stack through region of mutant anterior limb shown in [Figure 5F--J](#fig5){ref-type="fig"}.Please view as described above.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.022](10.7554/eLife.07897.022)10.7554/eLife.07897.023Figure 5---figure supplement 1.Digital image overlap of Tbx3 and Arl13b in limb bud anterior mesenchyme.(**A**) Maximum image projection of Arl13b channel from control limb z-stack shown in [Figure 5---source data 1](#SD2-data){ref-type="supplementary-material"}. Both mesenchymal and epithelial cilia are apparent in the maximum projection. (**B**) Calculated digital image overlap of Arl13b (cilia) and Tbx3 positive pixels in control limb bud. Note that all epithelial cilia in the stack are Tbx3 negative and of the 50 mesenchymal cilia, 18 (36%) are Tbx3 positive. Please see Experimental Procedures for use of Zen and Image J software to calculate pixel overlap in separate channels. (**C**) Maximum image projection of Arl13b channel from control limb z-stack shown in [Figure 5---source data 2](#SD3-data){ref-type="supplementary-material"}. Both mesenchymal and epithelial cilia are apparent in the maximum projection. (**D**) Calculated digital image overlap of Arl13b (cilia) and Tbx3 positive pixels in *Tbx3;PrxCre* limb bud. Note that all epithelial cilia in the stack are Tbx3 negative and of the 54 mesenchymal cilia, 2 (4%) are Tbx3 positive consistent with low level of background antibody staining in mutant ([Figure 5](#fig5){ref-type="fig"}, panels **G**, **I**).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.023](10.7554/eLife.07897.023)10.7554/eLife.07897.024Figure 5---figure supplement 2.Tbx3 immunoreactivity in limb cilia is also detected by a commercial anti-Tbx3 antibody against the N-terminus of Tbx3.(**A**) Maximum image projection of Arl13b channel from control forelimb z-stack. (**B**) Calculated digital image overlap (see Methods section) of Arl13b (cilia) and Tbx3 positive pixels in control limb bud shown above using Abcam (Abcam ab99302) anti-Tbx3 antibody to the N-terminus of mouse Tbx3. 27/97 (28%) of mesenchymal cilia are Tbx3+. (**C**) Maximum image projection of Arl13b channel from *Tbx3;PrxCre* mutant forelimb z-stack. (**D**) Calculated digital image overlap of Arl13b (cilia) and Tbx3 positive pixels in *Tbx3;PrxCre* forelimb bud shown above. 2/52 mesenchymal cilia are Tbx3+. (**E**) Scatter plot obtained using ImageJ comparing Tbx3 and Arl13b intensities from control and mutant anterior forelimb buds stained with Abcam anti-Tbx3 antibody shown in **A--D**.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.024](10.7554/eLife.07897.024)

Murine embryonic fibroblasts (MEFs) are a robust system for studying ciliary proteins ([@bib10]; [@bib16]; [@bib47]; [@bib67]; [@bib76]), so we used them to further explore Tbx3 localization and trafficking. In untreated wild type MEFs, our custom C-terminal antibody detected Tbx3 in a subset of cilia (30%, N=56; [Figure 6A and B, a1-a5, b1-b5](#fig6){ref-type="fig"}; [Figure 6---source data 1](#SD4-data){ref-type="supplementary-material"},[2](#SD5-data){ref-type="supplementary-material"}). No Tbx3+ cilia were detected in *Tbx3* null MEFS ([Figure 6C--F](#fig6){ref-type="fig"}; [Figure 6---source data 3](#SD6-data){ref-type="supplementary-material"}). Treatment of wild type MEFs with the smoothened agonist SAG increased the number of Tbx3+ cilia from 30% to 75% ([Figure 6G-J](#fig6){ref-type="fig"} p\<0.005, [Figure 6---source data 4](#SD7-data){ref-type="supplementary-material"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Lysates from control and SAG-treated MEFs showed no detectable difference in Tbx3 protein levels indicating the increased Tbx3 signal in cilia was due to trafficking rather than increased protein levels ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). The presence of Tbx3 in cilia and response to Hedgehog pathway activity were also detected with a commercially available anti-Tbx3 antibody with both SAG and Shh stimulation ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"} and [Figure 6---source data 5](#SD8-data){ref-type="supplementary-material"},[6](#SD9-data){ref-type="supplementary-material"}). In total, these data show that Tbx3 is present at baseline in cilia, and is trafficked to cilia in response to hedgehog signaling.10.7554/eLife.07897.025Figure 6.Tbx3 is present in some cilia at baseline in Murine Embryonic Fibroblasts and trafficks to cilia in response to hedgehog pathway activation.(**A**, **B**) Confocal, 100X single z-plane immunofluorescence images from two different fields of wild type MEFS after immunostaining for: DAPI (DNA, blue), Tbx3 (green, c-terminal anti-Tbx3 antibody; [@bib22]), Arl13b (red, cilia). White boxed regions outline single cells that are shown at higher magnification in panels **a1--a5** and **b1**--**b5**. Please see [Figure 6---source data 1](#SD4-data){ref-type="supplementary-material"},[2](#SD5-data){ref-type="supplementary-material"} for z-stacks. **a1**--**a4**, **b1**--**b4**) Single cells from white boxed areas in panels A and B. Individual cilia are shown in a5 and b5. White arrowheads highlight Tbx3+ cilia. (**C**--**F**) Tbx3 null MEFs show loss of Tbx3 immunoreactivity in cilia and other cellular locations. Please see [Figure 6---source data 3](#SD6-data){ref-type="supplementary-material"} for z-stack. (**G**--**J**) As in **A** and **B**, but MEFs were treated with smoothened agonist (SAG). White arrowheads highlight Tbx3+ cilia. Please see [Figure 6---source data 4](#SD7-data){ref-type="supplementary-material"} for z-stack.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.025](10.7554/eLife.07897.025)10.7554/eLife.07897.026Figure 6---source data 1.Czi file showing z-stack of wild type MEFs imaged in [Figure 6](#fig6){ref-type="fig"} panel A.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.026](10.7554/eLife.07897.026)10.7554/eLife.07897.027Figure 6---source data 2.Czi file showing z-stack of wild type MEFs imaged in [Figure 6](#fig6){ref-type="fig"} panel B.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.027](10.7554/eLife.07897.027)10.7554/eLife.07897.028Figure 6---source data 3.Czi file showing z-stack of Tbx3 null MEFs imaged in [Figure 6](#fig6){ref-type="fig"} panel C--F.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.028](10.7554/eLife.07897.028)10.7554/eLife.07897.029Figure 6---source data 4.Czi file showing z-stack of SAG treated MEFs imaged in [Figure 6](#fig6){ref-type="fig"} panel G--J.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.029](10.7554/eLife.07897.029)10.7554/eLife.07897.030Figure 6---source data 5.Czi file showing z-stack of SAG treated MEFs imaged in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} panel C.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.030](10.7554/eLife.07897.030)10.7554/eLife.07897.031Figure 6---source data 6.Czi file showing z-stack of SHH treated MEFs imaged in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} panel D.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.031](10.7554/eLife.07897.031)10.7554/eLife.07897.032Figure 6---figure supplement 1.Tbx3 immunoreactivity in cilia increases in response to Hedgehog pathway stimulation without an overall increase in Tbx3 protein levels.(**A**) Quantitation of Tbx3+ cilia in wild type MEFS -/+ SAG shows marked increase in Tbx3 immunoreactive cilia in response to SAG. B) Western blot assaying Tbx3 and btubulin (loading control) protein levels in MEFs +/- SAG; the increase in number of Tbx3+ cilia occurs without an increase in amount of total Tbx3 protein. (**C**, **D**) Immunofluorescence images of SAG-treated (**C**) or SHH (**D**) MEFs assayed with a Santa Cruz commercial anti-Tbx3 antibody (A20) raised against an internal Tbx3 epitope (green) confirm colocalization with cilia/Arl13b (red). These merged images include DAPI in blue; white arrowheads highlight ciliary Tbx3. Please see [Figure 6---source data 5](#SD8-data){ref-type="supplementary-material"},[6](#SD9-data){ref-type="supplementary-material"} for z-stacks.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.032](10.7554/eLife.07897.032)

Tbx3 co-localizes with Gli3 in the primary cilia {#s2-8}
------------------------------------------------

The presence of Tbx3 in cilia and the known association of Gli3 and Kif7 in primary cilia ([@bib17]) led us to test for interaction between endogenous Tbx3 and Gli3. Co-immunoprecipitation of E10.5 forelimb lysates showed that Tbx3 co-IPs with endogenous Gli3 ([Figure 7A](#fig7){ref-type="fig"}, and with Kif7 as shown previously), and that both Gli3FL and Gli3R are complexed with Tbx3 in the limb bud ([Figure 7B](#fig7){ref-type="fig"}, lane 1). These interactions are also detected in whole embryos ([Figure 7C](#fig7){ref-type="fig"}; specificity/efficiency of Gli3 and Kif7 IPs are shown in [Figure 7C' and C"](#fig7){ref-type="fig"}, respectively. Additional experiments showing this interaction are in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Overexpression of Flag-tagged Gli3 and Myc-tagged Tbx3 in HEK293 cells followed by co-immunoprecipitation did not indicate direct interaction in this cellular context ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), suggesting that their association occurs within a larger complex that includes Kif7 ([Figure 4](#fig4){ref-type="fig"}).10.7554/eLife.07897.033Figure 7.Tbx3 interacts with Gli3 in the limb bud and trafficks with Gli3 in primary cilia.(**A**, **B**) Immunoprecipitation (IP) of E10.5 forelimb bud protein lysates with antibodies listed at the top of panel and immunoblotted (IB) to detect Tbx3 (**A**) or Gli3 (**B**). Black arrowhead indicates IgG. Gli3FL and Gli3R (red arrowheads in B) both co-immunoprecipitate with Tbx3. (**C**) Immunoprecipitation (IP) of E10.5 whole embryo protein lysates with antibodies listed at the top of panel and immunoblotted to detect Tbx3. Tbx3 co-IPs with Gli3. Specificity and efficiency of anti-Gi3 and anti-Kif7 antibodies in whole embryo lysates tested are shown in panels **C'** and **C"**. Additional experiments demonstrating Tbx3/Gli3 interactions are in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}. Em, empty lane (**D--I'**) Confocal 100X single Z-plane immunofluorescence images of vehicle (DMSO) treated MEFS after immunostaining for: DAPI (DNA, blue), Tbx3 (green, [@bib22]), Gli3 (red), Arl13b (pink, cilia). Panel **H** is merged image of (**D**--**G**). Panel I is 2.5X digital zoom of the boxed cell in panel **H**, and **I'** shows the pink (cilia) channel pixel shifted to permit visualization of colocalized Tbx3 and Gli3 (yellow) within the cilia. White arrowheads highlight Gli3/Tbx3 colocalization. Please see [Figure 7---source data 1](#SD10-data){ref-type="supplementary-material"} for z-stacks. (**J**--**O'**) As above, but MEFS were treated with SAG in DMSO. Please see [Figure 7---source data 2](#SD11-data){ref-type="supplementary-material"} for z-stack. (**P**) Quantitation of Tbx3+ and Gli3+ cilia in MEFS -/+ SAG. SAG treatment causes the majority of cilia to become Tbx3+ and these ciliary Tbx3 signals all colocalize with Gli3.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.033](10.7554/eLife.07897.033)10.7554/eLife.07897.034Figure 7---source data 1.Czi file showing z-stack of wild type MEFs imaged in [Figure 7](#fig7){ref-type="fig"} panel D-I'.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.034](10.7554/eLife.07897.034)10.7554/eLife.07897.035Figure 7---source data 2.Czi file showing z-stack of SAG treated MEFs imaged in [Figure 7](#fig7){ref-type="fig"} panel J-O'.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.035](10.7554/eLife.07897.035)10.7554/eLife.07897.036Figure 7---figure supplement 1.Tbx3 and Gli3 coimmunoprecipitate in whole embryo protein lysates.(**A, B**) Immunoprecipitation (IP) of E10.5 whole embryo protein lysates with antibodies listed at top of panels and immunoblotted (IB) to detect Tbx3 (**A**) or Gli3 (**B**). Black arrowhead indicates IgG. Gli3FL and Gli3R (red arrowheads in **B**) both co-immunoprecipitate with Tbx3. Em, empty lane**DOI:** [http://dx.doi.org/10.7554/eLife.07897.036](10.7554/eLife.07897.036)10.7554/eLife.07897.037Figure 7---figure supplement 2.Tagged Tbx3 does not co-IP with tagged Gli3 in HEK293 cells.Co-IP assay of Myc-tagged Tbx3 and Flag-tagged Gli3 overexpressed in HEK293 cells. IP was performed with antibodies listed at top and immunoblotted for Gli3. Myc-tagged Tbx3 does not interact with tagged Gli3.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.037](10.7554/eLife.07897.037)10.7554/eLife.07897.038Figure 7---figure supplement 3.Tbx3 does not co-IP with Sufu or Spop in mouse embryo lysates.(**A**, **B**) Immunoprecipitations/Immunoblot assaying for interaction between endogenous Tbx3 and Sufu in E10.5 mouse embryo lysates. Sufu did not co-IP Tbx3 (**A**) nor did Tbx3 co-IP Sufu (**B**). (**C**) Immunoprecipitations/Immunoblot assaying for interaction between Tbx3 and Spop in control and *Tbx3^Δfl/Δfl^*E10.5 mouse embryo lysates. No interaction was detected. Note increased Spop in mutant, consistent with previous result in [Figure 4J](#fig4){ref-type="fig"} and data in [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.038](10.7554/eLife.07897.038)

Immunofluorescence assay of untreated MEFs for Tbx3, Gli3, and Arl13b by triple immunocytochemistry showed that 90% of cilia were Gli3+; Tbx3 colocalized with 66% of the Gli3 signals (N=38 total cilia scored, [Figure 7D--I](#fig7){ref-type="fig"}' [Figure 7---source data 1](#SD10-data){ref-type="supplementary-material"}). Treatment with SAG increased the fraction of Gli3+ cilia to \>95% and all but two of those Gli3 signals colocalized with Tbx3 (N=34, [Figure 7J--O](#fig7){ref-type="fig"}', [Figure 7---source data 2](#SD11-data){ref-type="supplementary-material"}). These results are quantified in [Figure 7P](#fig7){ref-type="fig"}.

Loss of Tbx3 compromises the Sufu/Kif7 complex required for Gli3FL stability and normal processing of Gli3R {#s2-9}
-----------------------------------------------------------------------------------------------------------

To obtain further mechanistic understanding into how loss of Tbx3 results in decreased Gli3 proteins, we assayed levels and interactions of members of the Gli3 processing machinery. Gli3FL stability and partial processing versus complete degradation are regulated by opposing actions of Suppressor of fused (Sufu) and speckle-type POZ protein (Spop), respectively ([@bib95]; [@bib98]). In the absence of Smoothened activation, mammalian Sufu recruits GSK3β to phosphorylate Gli3FL downstream of PKA, allowing for its partial processing to Gli3R (which requires Kif7 and intact cilia) ([@bib39]; [@bib88]; [@bib91]). Spop is an adaptor for Cullin3-based E3 ubiquitin ligase that drives complete degradation of Gli3FL in the absence of Sufu, but facilitates its processing to Gli3R when Sufu is present ([@bib35]; [@bib95]; [@bib102]). In contrast to Kif7 and Gli3, we did not detect interactions between Tbx3 and either Sufu or Spop ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). The observation that Gli3FL is virtually undetectable in *Tbx3;PrxCre* anterior mesenchyme ([Figure 4A\'](#fig4){ref-type="fig"}) indicates that despite the increased amount of Sufu ([Figure 4H](#fig4){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), it fails to prevent degradation of Gli3FL in the absence of Tbx3.

We next tested whether decreased levels of Gli3 proteins in the anterior mesenchyme reflected perturbed interactions between Sufu, Gli3 and Kif7. Limitations in sample quantity made it unfeasible to perform multiple co-IPs on isolated anterior forelimb buds, so we assayed lysates from control and *Tbx3^Δfl/Δfl^* E10.5 embryos. The altered levels of protein expression seen in mutant limb buds were recapitulated in whole embryos ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). As seen in mutant limb buds, the amount of both Gli3FL and Gli3R protein is reduced in *Tbx3^Δfl/Δfl^* embryos ([Figure 8A](#fig8){ref-type="fig"}, lanes 1--4; [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}; [Figure 8---figure supplement 2A and B](#fig8s2){ref-type="fig"}). Notably, the interaction between Gli3 and Sufu is reproducibly decreased in excess of the decrement in Gli3 proteins; this is evident by quantitating and comparing the ratio of Gli3 proteins detected in control versus mutant to that complexed with Sufu. For example, in the representative experiment shown in [Figure 8A](#fig8){ref-type="fig"}, the Gli3 FL band intensity ratio is \~1.6 fold greater in controls ([Figure 8A](#fig8){ref-type="fig"}, lanes 1 and 3) than in mutants ([Figure 8A](#fig8){ref-type="fig"}, lanes 2, 4), while the amount of Gli3FL protein that was immunoprecipitated with Sufu is 4.6 fold greater in controls than mutants ([Figure 8A](#fig8){ref-type="fig"}, lane 9 versus 10). Mean band intensity ratios of 3 replicate experiments are shown in [Figure 8A'](#fig8){ref-type="fig"}. The decreased Gli3/Sufu interaction in the absence of Tbx3 was also evident when assayed in the opposite direction, that is, by IP of Gli3 and immunoblotting for Sufu ([Figure 8B](#fig8){ref-type="fig"}, panel B' shows relative band intensities for the experiment shown). Sufu/Gli3R interactions were also affected ([Figure 8A](#fig8){ref-type="fig"}'; [Figure 8---figure supplement 2A--B](#fig8s2){ref-type="fig"}). These findings indicate that normal stoichiometry of the interaction of Gli3 proteins with Sufu requires Tbx3.10.7554/eLife.07897.039Figure 8.Altered stoichiometry of interactions between Gli3 and members of its processing/degradation complex.(**A**) Anti-Gli3 immunoblot (IB) on immunoprecipitates (IP) from antibodies listed at top on lysates from E10.5 control (wt) and *Tbx3^Δfl/Δfl^* (ko) embryos. Gli3FL and Gli3R are denoted by red arrowheads, IgG heavy chain with black arrowhead. Note decreased levels of IP'd Gli3FL and Gli3R in mutants compared with controls; the IPs in lanes 1--2 and 3--4 are two independent biologic replicates and the band intensity ratio of control to mutant for both GliFL and Gli3R was \~1.6. The interaction between Gli3 and Sufu is decreased more than can be explained by the overall decrement in Gli3 protein levels: in this representative experiment Sufu co-IPs 4.6X more Gli3FL in controls than in mutants (lane 9 versus 10). (**A'**) Bar graphs show the results of quantitation of band intensities from three3 replicate experiments measured with densitometry and presented as the ratio of signal detected in controls relative to mutants. (**B**) As in A but immunoblot probed for Sufu. Comparison of lanes 1 and 2 confirms decreased interaction between Gli3 and Sufu, despite preserved levels of Sufu in the mutants (lane 10). (**C**) Anti-Gli3 immunoblot with IPs as listed at top. Note increased interaction between Kif7 and Gli3 in mutants (lane 4), despite overall decreased level of Gli3 (lane 8). (**C'**) Quantitation of band intensities from three replicate experiments measured with densitometry and presented as a ratio of signal detected in control relative to mutant. Even though there is less total Gli3 protein, since there is increased interaction between Gli3 and Kif7 in mutants, the Kif7 co-IP control to mutant ratios are \<1. (**D**) Anti-Kif7 immunoblot with IPs as listed at top. Confirms increased interaction between Gli3 and Kif7 in mutants. (**D'**) Quantitation of experiment in **D**. (**E**) Anti-Kif7 immunoblot with IPs as listed at top. The interaction of Kif7 and Sufu is decreased in the absence of Tbx3 (lane 4) despite preserved levels of both proteins (lane 6; [Figure 8](#fig8){ref-type="fig"}, panels **B**, **D** and **F**; [Figure 8---figure supplements 1](#fig8s1){ref-type="fig"} and [2](#fig8s2){ref-type="fig"}). (**E'**) Quantitation of band intensities from two replicate experiments measured with densitometry and presented as ratio of signal detected in control relative to mutant. There is 2 fold less interaction between Kif7 and Sufu in mutants. (**F**) Anti-Sufu immunoblot with IPs as listed at top. The interaction of Kif7 and Sufu is decreased in the absence of Tbx3 (lane 3 versus 4). (**F'**) Quantitation of findings in **F**.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.039](10.7554/eLife.07897.039)10.7554/eLife.07897.040Figure 8---figure supplement 1.Altered protein levels observed in mutant limb buds are also apparent in whole embryos.(**A**, **B**) Immunoblots on protein lysates prepared from E10.5 forelimb buds (**A**) and whole embryos (**B**). Actin is loading control. (**C**) Quantitation of protein levels in A and B comparing amount detected in control to mutant. Note increased levels of Sufu and Spop in mutant limbs and embryos that results in ratios of control to mutant \<1. nd, not detected**DOI:** [http://dx.doi.org/10.7554/eLife.07897.040](10.7554/eLife.07897.040)10.7554/eLife.07897.041Figure 8---figure supplement 2.Replicate experiments confirming altered stoichiometry of interactions between Gli3 and members of its processing complex in Tbx3 mutants.(**A**) Anti-Gli3 immunoblot (IB) on immunoprecipitates (IP) from antibodies listed at top on lysates from E10.5 control (wt) and *Tbx3^Δfl/Δfl^* (ko) embryos. Gli3FL and Gli3R are denoted by red arrowheads, IgG heavy chain by black arrowhead. Note decreased levels of IP'd Gli3R in mutants (lane 4) compared with control (lane 5). (**A'**) Quantitation of IPd proteins detected in A. The interaction between Gli3R and Sufu is decreased more than can be explained by the overall decrement in Gli3R protein levels: in this experiment, \>9 fold more Gli3R co-IPs with Sufu in controls than mutants (lanes 3 versus 4), whereas the decrement in Gli3R is only 3.8 fold (lanes 5 versus 6). (**B**, **B'**) Additional replicate co-IP experiment confirming decreased interaction between Gli3R and Sufu (lanes 7 and 8) in excess of decrement in overall Gli3R level (lanes 5 and 6). (**C**, **C'**) Anti-Gli3 immunoblot (IB) and quantitation of IPs from antibodies listed at top on lysates from E10.5 control (wt) and *Tbx3^Δfl/Δfl^* (ko) embryos. 3.3 fold [more]{.ul} Gli3R co-IPs with Kif7 in mutants (lane 2) than in controls (lane 1), despite an overall 2.9 fold [decrease]{.ul} in Gli3R levels (lanes 5 versus 6). (**D**, **D'**) Anti-Kif7 immunoblot (IB) and quantitation of IPs from antibodies listed at top on lysates from E10.5 control (wt) and *Tbx3^Δfl/Δfl^* (ko) embryos. In this example, the amount of Kif7 that co-IPs with Sufu is decreased in 2.4 fold in Tbx3 mutants, consistent with previous results shown in [Figure 8](#fig8){ref-type="fig"} panels **E** and **F**.**DOI:** [http://dx.doi.org/10.7554/eLife.07897.041](10.7554/eLife.07897.041)

In wild type embryos, we detected only trace interaction between Kif7 and Gli3R assaying by co-IP in either direction ([Figure 8C](#fig8){ref-type="fig"}, lane 3; [Figure 8D](#fig8){ref-type="fig"}, lane 7; [Figure 8---figure supplement 2C](#fig8s2){ref-type="fig"}, lane1). However, there was a robust and reproducible interaction in mutants despite the decrease in the total amount of Gli3 proteins. In the representative experiment shown in [Figure 8C](#fig8){ref-type="fig"}, in which we IP'd for Kif7 and assayed for Gli3, the band intensity ratios of control (lane 3) to mutant (lane 4) were 0.1 for Gli3FL and 0.25 for Gli3R. Quantification of the band intensity ratios from three replicate experiments in which we IP'd for Kif7 and assayed for Gli3 is shown in [Figure 8C](#fig8){ref-type="fig"}'. Furthermore, the increased interaction of Kif7 with Gli3 was confirmed by IP of Gli3 and assay for Kif7, as shown in [Figure 8D](#fig8){ref-type="fig"}: the band intensity ratio of control (lane 7) to mutant (lane 8) was 0.1, indicating a marked increase in interaction in mutants ([Figure 8D](#fig8){ref-type="fig"}' graphs relative band intensities in experiment 8D).

Lastly, the interaction between Sufu and Kif7 was reproducibly decreased when assayed by co-IP in either direction ([Figure 8E](#fig8){ref-type="fig"}, lane 3 versus 4; [Figure 8F](#fig8){ref-type="fig"}, lane 3 versus 4; [Figure 8---figure supplement 2D](#fig8s2){ref-type="fig"}, lane 7 versus 8). Quantification of the band intensity ratios from replicate experiments in which we IP'd for Sufu and assayed for Kif7 is shown in [Figure 8C](#fig8){ref-type="fig"}'. [Figure 8F](#fig8){ref-type="fig"}' graphs relative band intensities in experiment 8F in which we IP'd for Kif7 and assayed for Sufu. Note that this decrease in Sufu/Kif7 interaction occurs despite increased and normal levels of these proteins, respectively. In total, these data indicate that Tbx3 is required for normal stoichiometry and function of the Sufu/Kif7 complex that stabilizes and processes Gli3 as modeled in [Figure 9](#fig9){ref-type="fig"}.10.7554/eLife.07897.042Figure 9.Model of compartment specific functions of Tbx3 in forelimb bud mesenchyme and altered interactions and stoichiometry of the Kif7/Sufu Gli3 processing complex in *Tbx3;PrxCre* mutants.In posterior forelimb mesenchyme, Tbx3 is required for normal levels of Hand2 upstream of Shh. Shh pathway activity and other Tbx3-reponsive factors promote digit 5 formation. In the absence of Tbx3, there is decreased expression of Hand2 and Shh and other digit 5 promoting pathways. In anterior mesenchyme, Tbx3 is in a complex with Gli3 proteins, Kif7 and Sufu and required for the stability of Gli3 FL and Gli3R. In the absence of Tbx3, Sufu and Spop protein levels are increased yet there is decreased interaction between Sufu and Kif7, and Sufu and Gli3. In mutant anterior mesenchyme, Gli3FL is barely detected: it is either degraded or converted to Gli3R. Levels of Gli3R are abnormally low due to a combination of decreased amount of Gli3FL precursor and its processing to Gli3R, and excess degradation. These findings are consistent with decreased function of cilia and Kif7 (required for processing of Gli3FL to Gli3R), and of Sufu (required for stability of both Gli3FL and Gli3R).**DOI:** [http://dx.doi.org/10.7554/eLife.07897.042](10.7554/eLife.07897.042)

Discussion {#s3}
==========

Role of Tbx3 in limb bud initiation {#s3-1}
-----------------------------------

*Tbx3* expression in the LPM is required for normal *Tbx5* expression ([Figure 2A--C](#fig2){ref-type="fig"}) implicating *Tbx3* as one of the earliest limb initiation factors. This is consistent with our finding that Tbx3+ progenitors in the LPM give rise to the majority of limb bud mesenchyme. Determining the fate of these progenitors in the future will help reveal the mechanism for loss of ulna/fibula and digits 2--5 in *Tbx3* null embryos.

Differential sensitivity of the left and right limbs to Tbx3 {#s3-2}
------------------------------------------------------------

Intrinsic differences in anatomically bilaterally symmetric structures have long been suspected: acetazolamide teratogenizes only the right limb in rats ([@bib44]; [@bib100]) and nitroheterocyclics such as valproate also induce unilateral defects ([@bib14]; [@bib18]). Directional asymmetry in limb size in human fetuses was recently reported ([@bib89]). Left/right identity differences in bilaterally symmetric structures such as the limbs may be upstream of secondary patterning events such as dorsal/ventral axis appropriate to body side. Shiratori and colleagues reported asymmetric expression of Pitx2c in the developing mouse limb and postulated functional left/right differences ([@bib81]). Our finding that the left limb is more sensitive to Tbx3 than the right is consistent with this hypothesis and warrants further investigation in humans with UMS and other mouse models.

Discrete functions for Tbx3 in the anterior and posterior limb bud mesenchyme {#s3-3}
-----------------------------------------------------------------------------

A model of molecular mechanisms contributing to the different anterior and posterior limb phenotypes of *Tbx3;PrxCre* mutants is shown in [Figure 9](#fig9){ref-type="fig"}.

Digit 5 formation is exquisitely sensitive to Shh activity and Grem1 ([@bib26]; [@bib80]; [@bib104]; [@bib105]), so the altered expression of these genes in posterior mutant mesenchyme helps to explain loss of this digit. *Shh* null heterozygotes (*Shh*^+/-^) have normal digit number, suggesting that the loss of digit 5 in *Tbx3;PrxCre* mutants is not solely due to decreased *Shh* expression and pathway activity in posterior mesenchyme. Importantly, it is not known if compensatory mechanisms preserve normal Shh protein levels or activity in *Shh*^+/-^ mutants to support normal limb development. Indeed, a \'buffering system\' to modulate polarizing activity by Shh was proposed in the chick limb ([@bib78]).

We found evidence of dysfunction of other digit 5 promoting pathways in posterior mesenchyme of *Tbx3;PrxCre* mutants. Compound *Hand2/Gli3* null mutants have more severe polydactyly than *Gli3* mutants ([@bib23]), indicating that the role of Hand2 in digit formation is not limited to regulation of *Shh* expression. Aberrant expression of other BHLH factors ([Supplementary files 1](#SD12-data){ref-type="supplementary-material"},[3](#SD14-data){ref-type="supplementary-material"}: *Hand1, Bhlhe40, Bhlh*e*41, Bhlh*a*15*) may also contribute to the phenotype because the stoichiometry and interactions of BHLH factors have complex roles in limb development ([@bib20]). Altered levels of BMP responsive targets (*Dkk1, Noggin, Grem1, Grem2*) in *Tbx3;PrxCre* mutants suggest disrupted BMP signaling. Overexpression of *Gata6* decreases *Shh* and *Grem1* expression and causes loss of posterior digits ([@bib40]); we detected increased *Gata6* expression in the posterior mesenchyme of *Tbx3;PrxCre* mutants ([Supplementary file 3](#SD14-data){ref-type="supplementary-material"}). Additional studies are needed to determine if Tbx3 transcriptional or post-transcriptional functions directly regulate these pathways.

Although Tbx3 is also present in posterior mesenchymal cilia, we did not detect any evidence of altered stability or processing of Gli3 in the posterior mesenchyme ([Figure 4A](#fig4){ref-type="fig"}, representative of three replicates). Nonetheless, it is possible that decreased Shh signaling in the posterior of *Tbx3;PrxCre* mutant limb buds creates changes in Gli3 levels/ratios below our ability to detect. If so, decreased Shh activity would be predicted to increase Gli3R, decreasing digit number.

It is notable that decreased expression of *Tbx2* observed in *Tbx3;PrxCre* mutants would be predicted to result in increased *Grem1* expression ([@bib19]) however, *Grem1* expression is decreased ([Figure 3](#fig3){ref-type="fig"}). Decreased Shh signaling and *Grem1* expression in the posterior mesenchyme would both be predicted to result in decreased *Fgf4* and *Fgf8* expression in the posterior AER ([@bib38]; [@bib60]). Rather, the finding that these transcripts are increased in the posterior ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}) indicates that loss of Tbx3 in posterior mesenchyme disrupts the Shh-Grem1-FGF signaling loop.

In wild type anterior mesenchyme, our data support the model that Tbx3 is part of a Kif7/Sufu complex that drives processing of the majority of Gli3FL to Gli3R and also prevents complete degradation of Gli3FL by Spop ([@bib95]). Note that our model and data show a marked decrease in Gli3FL (virtually undetectable by western blot in anterior mesenchyme), but residual Gli3R in mutants. This is consistent with the phenotype of Gli3 deficiency, and digit 1 polysyndactyly is also seen with decreased function of Kif7 or Sufu. Residual Gli3R in the mutants is sufficient to prevent the extreme polydactyly seen in complete absence of Gli3, Kif7 or Sufu. In *Tbx3;PrxCre* mutant limb buds, Kif7 and Sufu proteins are present at normal and increased levels, respectively, but their interaction with each other, and that of Sufu with Gli3, are decreased. Because Spop facilitates processing of Gli3FL to Gli3R in the presence of Sufu, increased levels of Spop in mutants drives complete degradation of any Gli3FL not converted to Gli3R, resulting in undetectable levels of Gli3FL in anterior mesenchyme. The decreased levels of Gli3R in the anterior likely result from a combination of decreased levels of Gli3FL precursor, inefficient processing due to altered Kif7/Sufu function, and excess Gli3R degradation, as evident by the lower molecular weight species present in [Figure 3A](#fig3){ref-type="fig"}.

This synthesis is consistent with the large body of published data indicating that anterior digit number is tightly regulated by the balance of Gli3A and Gli3R, in turn controlled by Kif7 and Sufu ([@bib9]; [@bib91]; [@bib94]; [@bib96]; [@bib107]). Kif7^-/-^ and other ciliary mutants maintain robust levels of Gli3FL but have a marked decrease in processing it to Gli3R and their PPD phenotypes are consistent with decreased Gli3R ([@bib12]; [@bib17]). Furthermore, recent studies from Chi Chung Hui's group demonstrate that *Kif7;PrxCre* mutants have anterior PPD and that increasing Gli3R or decreasing Gli activators rescues all but digit 1 duplication ([@bib106]).

*Tbx3* mutant limbs also display evidence of Sufu dysfunction with markedly decreased levels of Gli3R and absent Gli3FL. Levels of Gli2, Gli3FL and Gli3R are all drastically reduced in *Sufu* mutants, even in the absence of cilia, consistent with the fact that Spop is not a ciliary protein and drives degradation of the full length proteins in the absence of Sufu ([@bib10]; [@bib36]; [@bib86]; [@bib95]). However, βTrCP and Spop can only mediate [processing]{.ul} of Gli3FL to Gli3R in the presence of both Sufu and Kif7/intact cilia/intraflagellar transport ([@bib17]; [@bib43]; [@bib51]; [@bib95]; [@bib98]). This processing is believed to occur at the basal body/centrosome ([@bib77]; [@bib93]; [@bib98]; [@bib99]). Thus, our data strongly support that Tbx3 functions at the cilia or basal body, as a part of the complex that regulates Gli3 processing and stability ([@bib77]; [@bib98]).

Loss of Tbx3 could also influence stability and processing of Gli2. The anterior PPD phenotype of *Gli3* heterozygotes is slightly more severe in a *Gli2* null background ([@bib6]; [@bib62]). Gli2 is also expressed in the posterior mesenchyme where it regulates digit patterning but not digit number ([@bib6]). Bowers' study also demonstrated that the role of Gli activators is in AP patterning of the posterior limb, whereas Gli repressors regulate digit number and anterior limb AP patterning. This is consistent with our findings that Tbx3 affects anterior digit number by regulating Gli3 repressor stability in the anterior mesenchyme.

The functional significance of increased interaction between Kif7 and Gli3R that we detect in mutants requires additional study nonetheless, since the anterior phenotype of *Tbx3;PrxCre* mutants is one of Gli3R deficiency rather than absence, we conclude that either there is a pool of Gli3R unbound by Kif7 and/or Gli3R complexed with Kif7 still has repressor function.

In addition to its function as a Gli3R co-repressor, Zic3 also regulates cilia morphogenesis and function ([@bib85]). Since decreasing Zic3 levels in *Gli3^+/-^*mutants rescues their preaxial polydactyly ([@bib74]), *Zic3* overexpression in *Tbx3;PrxCre* mutants may contribute to the PPD phenotype.

Our data exclude ectopic Shh pathway activity as a cause of the PPD in *Tbx3;PrxCre* mutants: using multiple methods at multiple stages, we did not detect anterior *Shh, Gli1,* or *Ptch1* expression in the anterior mesenchyme. Notably, expression of the BMP antagonist *Grem1* is normally increased in PPD associated with ectopic anterior Shh pathway activity ([@bib54]; [@bib103]), but in *Tbx3* mutants, *Grem1* expression is markedly decreased. This is additional evidence in support of unique Tbx3-dependent pathways regulating digit number.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

Experiments were conducted in strict compliance with IACUC/AALAC standards. The *Tbx3^fl^*allele was detailed in [@bib22]. *Prx1Cre, RARCre* and *Rosa26^LacZ^* were previously reported ([@bib83]; [@bib63]; [@bib53]). Generation of the *Fgf8^mcm^* and *Tbx3^mcm^* alleles will be described elsewhere.

β-Galactosidase detection {#s4-2}
-------------------------

Males bearing *Fgf8^MCM^* or *Tbx3^MCM^*alleles were crossed with *Rosa26^LacZ/+^*females. Females were gavaged with tamoxifen (10mg/gm body weight) at stages stated in text. β−galactosidase activity was assayed using established protocols ([@bib70]).

Skeletal preparations {#s4-3}
---------------------

E15.5 fetuses were fixed in 4% PFA overnight, rinsed in water for 2 days and alcian blue stained for 30 hr, then cleared in BABB. Older specimens were processed as in Moon et al. (2000).

Whole mount RNA in situ hybridization {#s4-4}
-------------------------------------

Digoxigenin-labeled riboprobes were generated according to manufacturer's instructions (Roche). Embryos were processed using a standard protocol ([@bib70]).

RNA isolation and reverse transcription--qPCR analysis {#s4-5}
------------------------------------------------------

Total RNA preparation, cDNA generation and qPCR were carried out as described in [@bib101]. Primer sequences are provided in [Supplementary file 5](#SD16-data){ref-type="supplementary-material"}. All qPCRs were performed on a minimum of three biologic replicates of pooled forelimb buds ([Figure 3](#fig3){ref-type="fig"}) or anterior and posterior forelimb bud segments ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

Gene expression analyses by microarray {#s4-6}
--------------------------------------

Total RNA was prepared from three pools of dissected E10.25 control (*Tbx3 ^fl/+^*) and *Tbx3;PrxCre* mutant forelimbs using the RNAeasy Micro Kit (Qiagen 74004). The microarray and genomic analysis and bioinformatics core facilities at the University of Utah performed Agilent mouse whole-genome expression arrays and array image data analysis using Agilent Feature Extraction software. Subtle intensity-dependent bias was corrected with LOWESS normalization, with no background subtraction. Statistical analysis of normalized log-transformed data was performed in GeneSifter ([www.genesifter.net](www.genesifter.net)). Differentially expressed transcripts were defined (adjusted for multiple testing using the Benjamini and Hochberg method) as p\<0.05. The results presented in [Supplementary file 1](#SD12-data){ref-type="supplementary-material"} show transcripts that were statistically differentially expressed +/-1.3 fold in the mutant limb buds; yellow highlighting indicates changes that were replicated by RNA-Seq.

RNA-sequencing to detect differential gene expression {#s4-7}
-----------------------------------------------------

Total RNA was isolated from pools of dissected anterior and posterior regions of E11 control (*Tbx3^fl/+^*) and *Tbx3;PrxCre* forelimbs using the RNAeasy Micro Kit (Qiagen). Each pool contained 12 forelimbs and two biologic duplicate pools were assayed. cDNA was generated, sequenced, and raw sequence reads were processed as described in [@bib42]. [Supplementary file 2](#SD13-data){ref-type="supplementary-material"} contains transcripts that are differentially expressed +/-1.3 fold (+/-0.38 in log base 2, column L) in control anterior (CA) compared to control posterior (CP) limb segments. The transcripts listed in [Supplementary file 3](#SD14-data){ref-type="supplementary-material"} were the result of mining the data to detect differential expression +/-1.3 fold (+/- 0.38 in log base 2, column L) in control posterior (CP) relative to mutant posterior (MP) segments. [Supplementary file 4](#SD15-data){ref-type="supplementary-material"} shows the result of mining the data to detect differential expression +/-1.3 fold (+/-0.38 in log base 2, column L) in control anterior (CA) relative to mutant anterior (MA) limb segments.

Note that transcripts that were not differentially expressed +/-1.3 fold are not listed on the tables. The complete unmined dataset is available on GEO.

Immunoblotting {#s4-8}
--------------

Protein lysates were prepared from E10.5 dissected limb buds or embryos or cultured MEFs using Dignam buffer. 50 ug of total protein were then subjected to SDS-PAGE analysis followed by immunoblotting according to standard protocols. Primary antibodies: Sufu (\#2522, Cell signaling), Spop (\#PA5-28522), Myc (\#SC-789, Santa Cruz), Flag (\#F7425, Sigma), E2F1 (\#137415, Abcam), Ubiquitin (\#7780, Abcam), Gli3 (AF3690, R and D systems), Tbx3 C-terminal antibody ([@bib22]); Kif7 (ab 95884, Abcam); β tubulin (Santa Cruz).

Immunoprecipitations {#s4-9}
--------------------

Immunoprecipitations were performed as described in [@bib41] and [@bib42]. Briefly, protein lysates were prepared from limb buds or embryos at E10.5 or transfected HEK293 cells using Dignam buffer C. Cleared protein lysates were obtained by centrifugation at 12,000g for 10 min. Equal amounts of protein lysates were incubated with 5--10μg of respective antibodies over night at 4°C with gentle shaking. Immune complexes were isolated with Protein-G Dynal beads and washed three times with Dignam buffer C. Precipitates were eluted from the beads by boiling in SDS-loading dye for 10 min, and analysed by western blotting by standard procedures using indicated antibodies at a dilution of 1:1000.

Densitometry analysis {#s4-10}
---------------------

Immunoblot signals were quantified by densitometry using ImageJ64 software as per the procedure described by Luke Miller (<http://www.lukemiller.org/ImageJ_gel_analysis.pdf>).

Immunofluorescence of sectioned and intact limb buds {#s4-11}
----------------------------------------------------

Sections: Samples were fixed in 4% PFA at 4°C for 2 hr then washed with 0.3% Triton-X100 (in PBST). Heat retrieval in citrate buffer (Vector Laboratories) was performed for 2 min in a pressure cooker. Slides were washed with PBST and incubated in PBST with 5% serum corresponding to the secondary antibody origin for 1 hr. Slides were incubated with primary antibody in PBST 5% serum overnight at 4^°^C. Primary antibodies and dilutions: Tbx3 C-terminal antibody 1/200 ([@bib22]), Tbx3 N- terminal antibody 1/100 (Abcam ab99302), Tbx3 internal epitope antibody (Santa Cruz A-20), Arl13b 1/100 (USDavis/NIH NeuroMab Clone N259B/66), Gli3 1/100 (R&D systems AF3690), pHH3 (Ser10), Millipore 06--570(1:2000); (1:50); Kif7 (1:200, kind gift from Dr. C-c Hui). After washing in PBST for 15 min, slides were incubated with secondary antibody from either Invitrogen or Jackson Immunoresearch diluted 1/1000 in PBST 2% BSA with Hoechst 33,342 at 1ug/ml for 1h at room temperature. Final wash was with PBST for 15 min and mounted using Fluoromount-G from Southern Biotech. Secondary antibodies: Donkey anti-rabbit Alexa 488; Donkey anti-goat Alexa 488; Donkey anti-mouse Alexa 647; Donkey anti-goat Alexa 594.

Whole forelimb buds: samples were fixed in 4% PFA for 1 hr at room temperature with PBST. Heat retrieval in citrate buffer (Vector Laboratories) was performed for 5 min at 100^°^C followed by washing with PBST. Limb buds were incubated in PBST with 5% serum that correspond to the secondary antibody origin (Goat or Donkey) for 2 hr. Limb buds were incubated with primary antibody in PBST with 5% serum overnight at 4^°^C, then washed with PBST once and incubated in PBST with 2% BSA for 4 hr. Incubated with secondary antibody and Hoechst as above with overnight at 4°C. Prior to imaging, samples were washed with PBST for 4 hrs and incubated in PBS/50% glycerol overnight.

[TUNEL]{.ul}: was performed as described in ([@bib70])

Confocal microscopy and image processing of immunofluorescence on intact limb buds {#s4-12}
----------------------------------------------------------------------------------

Imaging was performed using a Zeiss confocal microscope LSM710 with Zen black imaging software <http://www.zeiss.com/microscopy/en_us/downloads/zen.html>. 100x objective was used.

To generate the Arl13b/Tbx3 colocalization maps, we used Zen to define pixels in each plane of z that exceeded an arbitrary threshold of 0.1 relative intensity in both Arl13b and Tbx3 channels using the imaging calculation subtab in the image processing menu. This was followed by calculation of the maximum intensity projection. To quantitate Tbx3 positive cilia, the 3D object counter in ImageJ ([@bib4]) was used employing the "redirection" option to superimpose Arl13b+ objects into the Tbx3 channel.

Assaying cilia volume and length {#s4-13}
--------------------------------

Cilia volume was assayed by quantitating Arl13b signal on 100x images of sectioned forelimbs from four pairs of mutant and control embryos stained for Arl13b and analyzing resulting in ImageJ. Imaged were Gaussian blurred using radius equal to \'1\' and further 3D object counter was used to measure volumes and surface area with threshold of 900 out of 4000 range. Distributions and parameters of the volume distributions shown in [Figure 4---figure supplement 2A and B](#fig4s2){ref-type="fig"} were calculated in Excel.

We calculated that the surface area and volume of both WT and mutant cilia tightly fit the equation: Surface=8.01 X Volume^0.69^ ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}), which indicates that the cilia shapes are the same in the mutants and controls, and change size proportionally. In this case, the relative change in volume between mutant and control (Volume mutant)/(Volume control)=1.1747, which correspond to a change in length of 6%.

MEF Immunocytochemistry {#s4-14}
-----------------------

MEFs from E10.5 embryos were plated on fibronectin coated Matteks. MEFs were cultured and processed as in [@bib41]; cilia outgrowth was stimulated by culture in 0.5% FBS for 24 hr followed by incubation with 100 nM SAG or 100 nM SHH (Phoenix Pharmaceuticals) for 24 hr. Cells were washed 2x with PBS and fixed in 4% PFA for 20 min on ice, then washed 2X with PBS and permeabilized with 0.2% Triton X-100 in PBS for 10 min. After blocking in 5% donkey serum + 3% BSA for 1 hr, cells were incubated with anti-TBX3 (custom C-terminal or Santa Cruz sc-17871) and anti-Arl13b (1:50 NeuroMAb) at room temperature for 2 hr. Cells were washed 5 X 5 min in PBS and then incubated in secondary donkey anti-goat-488 or anti-rabbit 488 and donkey antimouse -594 (Jackson Immunoresearch). After washing 3 x 5min in PBS, cells were incubated in DAPI for 20 min. Cells were then washed 3X with PBS and mounted in Dabco for imaging. Images were captured on a Zeiss LSM-710 confocal microscope and processed using Zen software as described above.

Assaying protein interactions with transfected, tagged proteins {#s4-15}
---------------------------------------------------------------

HEK-293 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin. Cells were maintained in 5% C0^2^ incubator at 37°C. Myc- tagged full length TBX3 was generated as previously described ([@bib42]). The Flag-tagged Gli3 construct was obtained from Addgene (51246) and the Flag-tagged Kif7 construct was a kind gift of Kathryn Anderson. Transfections of plasmids were performed with Lipofectamine 2000 reagent (Invitrogen) as per the manufacturer's protocol.

We thank Drs. Chi-Chung Hui, Cliff Tabin and Kathyrn Anderson for generously providing the Kif7 polyclonal antibody, the *Prx1Cre* mouse line, and the Flag-tagged Kif7 construct, respectively. We thank Susan Mackem, Steven Vokes and Brian Harfe for helpful discussions and Diana Lim for creating the graphic art. We thank Peter Gallagher for technical assistance.
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Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols with WCR IACUC protocol number 203-14.

Additional files {#s6}
================

10.7554/eLife.07897.043

###### Differentially expressed transcripts detected by microarray of E10.25 control and *Tbx3;PrxCre* mutant forelimb buds.

Table contains statistically significant differentially expressed genes determined as described in Methods section. Column 1 contains mean processed signal intensity of 3 biologic replicates from control limb, column 2 contains mean processed signal intensity of 3 biologic replicates from mutant limb. Fold changes are shown in Column E (Ratio). Yellow highlight of Gene ID (column N) indicates finding reproduced by RNA-Seq.

**DOI:** [http://dx.doi.org/10.7554/eLife.07897.043](10.7554/eLife.07897.043)

10.7554/eLife.07897.044

###### Differentially expressed transcripts detected by RNA-Seq of E11 control anterior forelimb buds versus control posterior forelimb buds.

Transcripts that are differentially expressed +/- 1.3 fold (+/- 0.38 in log base 2, column L) based on mean FPKM values in control posterior (CP, column O) compared to control anterior (CA, column P) limb segments. Values for each biologic replicate are in columns Q-T.

**DOI:** [http://dx.doi.org/10.7554/eLife.07897.044](10.7554/eLife.07897.044)

10.7554/eLife.07897.045

###### Differentially expressed transcripts detected by RNA-Seq of E11 control posterior forelimb buds versus *Tbx3;PrxCre* posterior forelimb buds.

Transcripts that are differentially expressed +/- 1.3 fold (+/- 0.38 in log base 2, column L) based on mean FPKM values in mutant posterior (MP, column O) compared to control posterior (CP, column P) limb segments. Values for each biologic replicate are in columns Q-T.

**DOI:** [http://dx.doi.org/10.7554/eLife.07897.045](10.7554/eLife.07897.045)

10.7554/eLife.07897.046

###### Differentially expressed transcripts detected by RNA-Seq of E11 control anterior forelimb buds versus *Tbx3;PrxCre* anterior forelimb buds.

Transcripts that are differentially expressed +/- 1.3 fold (+/- 0.38 in log base 2, column L) based on mean FPKM values in mutant anterior (MA, column O) compared to control anterior (CA, column P) limb segments. Values for each biologic replicate are in columns Q-T.

**DOI:** [http://dx.doi.org/10.7554/eLife.07897.046](10.7554/eLife.07897.046)

10.7554/eLife.07897.047

###### qPCR primer sequences.

**DOI:** [http://dx.doi.org/10.7554/eLife.07897.047](10.7554/eLife.07897.047)

10.7554/eLife.07897.048
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for choosing to send your work entitled \"Tbx3 is a Ciliary Protein that Regulates Gli3 Stability to Control Digit Number\" for consideration at *eLife*. Your full submission has been evaluated by Janet Rossant (Senior editor) and three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the decision was reached after discussions between the reviewers. Based on our discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

All referees agreed that the part of the paper describing the phenotype of Tbx3 loss in limb development is solid, and thus the comments concerning this part were relatively minor. However, the referees were much more skeptical about the strength of the experimental support for the most novel and interesting claim, the localization of Tbx3 to the cilia and the interaction of Tbx3 with the Hedgehog pathway components such as KIF7. Both the biochemical and subcellular localization experiments would need to be very significantly extended (for example, by using tagged proteins for immunoprecipitation assays), and more thorough controls for these experiments would need to be included. Also the strength and the value of the RNA-seq data presented in the paper were questioned, and these data thus need to be improved. Taken together, it appears that very significant additional work will be necessary to make the story convincing.

*Reviewer \#1:*

This paper describes the role of Tbx3 in limb development and connects this function to cilia-dependent regulation of the Hedgehog pathway. The authors use conditional ablation of Tbx3 to characterize in detail its role in limb formation. The authors also show that Tbx3 localizes to cilia, interacts with Gli3 and Kif7 and affects the formation of protein complexes involved in Hedgehog signaling.

I think that the paper is interesting and potentially suitable for publication in e*Life*. However, while the phenotypic description of Tbx3 loss appears solid to me, the part describing the biochemical interactions and ciliary localization of Tbx3 misses important controls and is therefore less convincing.

1\) [Figure 5A](#fig5){ref-type="fig"}: it is very surprising that Tbx3 precipitates with equal efficiency with Tbx3 and Kif7 antibodies. Anti-Kif7 blot must be included here to show the efficiency of Kif7 immunoprecipitation. In the legend, the% of input loaded must be indicated, so that the efficiency of immunoprecipitation can be estimated.

A similar comment applies to [Figure 6O](#fig6){ref-type="fig"}. A Tbx3 blot must be included in this panel, as well as the input lanes, so that the efficiency of immunoprecipitation can be estimated. The loading of IgG in the control lane seems to be lower than in the two other lanes, which makes the value of this control doubtful. It would be preferable, instead of IgG, to use as a negative control antibodies against another protein, which does not bind to Gli3 or Tbx3.

Similar comments also apply to the blots shown in [Figure 7E, G](#fig7){ref-type="fig"} and H. Arl13 blot should be shown in panel E, Kif7 blot in panel G and Sufu blot in panel H. Are the cut blots in panel E (including input lanes) derived from the same or different gels and do they show the same exposures? The observed differences in immunoprecipitation efficiency are not convincing and therefore need to be quantified using three independent experiments for all data shown in [Figure 7](#fig7){ref-type="fig"}.

2\) Are there any indications that the interactions of Tbx3 with Kif7 and Gli3 might be direct? For example, do these proteins co-immunoprecipitate when overexpressed in cultured cells?

3\) The specificity of the Tbx3 staining in cilia ([Figure 6](#fig6){ref-type="fig"}) must be confirmed using Tbx3 knockout cells.

*Reviewer \#2:*

This is an extensive body of work using a range of genetic tools and molecular approaches to tease apart the function(s) of Tbx3 in the limb.

The first part of the paper describes an analysis of the phenotypes produced following conditional deletion of Tbx3 at different times and places during limb development using a variety of cre lines. I have relatively minor comments on this.

The second, and main part of the paper ([Figures 5](#fig5){ref-type="fig"}--[8](#fig8){ref-type="fig"}) covers all the work from which the title of the manuscript derive. I have several concerns here and in general remain skeptical (but with an open mind) about the data and particularly the interpretation.

In many instances I feel the authors have gone too far in their conclusions without the necessary experimental data to support the *final* conclusions.

First and foremost, immunostaining for Tbx3 and Arl13b on limb sections is interpreted as showing Tbx3 in limb mesenchymal cilia. Immunostaining of Tbx3 is throughout the entire cell and apparent co-expresssion with Arl13b could simply be explained by overlap in stain. Much higher resolution microscopy imaging that can circumvent these potential artifacts is required. The staining on MEFS do not clarify the issue. It is not clear why the Tbx3 staining pattern is so different in these cells from that shown in A-C. (Other issues such as the legend for panels H-K states 25/33 cilia were Tbx3+. I do not see more than 20 cells or so in this panel further compounding the problem) (It can also be argued that any patterns identified in MEFs may not have relevance to the limb.)

I also could not see a clear effect on KIf7 localization form the panels C in [Figure 5](#fig5){ref-type="fig"}. Table E appears to be an extreme way to show an apparent 8% difference on cilia length (I could not see where these numbers came from). This section ends with the conclusion that the data show that Tbx3 is present at baseline in cilia and is trafficked to and within cilia in response to hedgehog signaling. Unfortunately, I remain unconvinced of any of this.

There are similar issues with the data in [Figure 7](#fig7){ref-type="fig"}. Fundamentally I don\'t see clear evidence of co-expression of Tbx3, Gli3 Arl13b although I appreciate that IP data is also included.

The data on effect on GLi3 stability are potentially interesting but perplexing

What is the effect on Gli3 expression in the mutant limbs? It might be expected following reduction of hand2 and Shh expression in the mutant that Gli3 expression would be expanded but the western data would suggest not. Is there more GLi3FLin the MP? It is perhaps surprising that apparently equivalent levels of Gli3R are present in CP and MP.

The Tbx3 cKO is close (but I would not say identical to or a phenocopy of) a Het *Gli3* mutant. This is not conveyed in the final schematic which suggests a critical role of Tbx3 in Gli processing and that this in its absence *all* Gli processing is affected. I would expect a more profound polydactyly if this were the case. The actual \'polydactyly that presents lacks a structure that could be considered a true digit (1H, H\').

A further question raised is that if Tbx3 is playing such a critical role in Gli processing/Shh signalling in the anterior is it or why is it not playing a similar role in the posterior. This is not discussed and does not appear to have been studied.

Some other minor issues from [Figure 1](#fig1){ref-type="fig"} include:

1L: I do not see any loss of Sox9 activity in the region indicated with the red arrow head. This domain looks relatively normal to me.

I do not see clear evidence of a delay in ossification. In the text the authors conclude that this \"reveals a role for Tbx3 in later aspects of Indian hedgehog regulated bone morphogenesis." This has not been investigated to any extent and this type of comments goes far beyond what is actually shown in this paper. Also here the loss of the deltoid tuberosity need not have anything to do a direct effect on bone (cf Blitz, E, 2009).

Comparison of the phenotypes produced using the early acting (RARCre) and later acting (Prx1Cre) appears to show an effect of Tbx3 on the early stages of limb initiation that can be distinguished form later events of limb bud patterning through establishment of Shh in the posterior. A regulatory relationship between Tbx3, Hand2 and Shh has been reported in chick (Rallis, 2005).

Decreased expression of markers detected by RNAseq analysis is interpreted as evidence that fewer cells are undergoing condensation and chondrogenesis in posterior mesenchyme. This would be much better analyzing in a more direct way rather than making inferences from RNA-seq data.

Similarly, 5th digits agenesis is attributed to deceased cell number as opposed to decreased proliferation of digit 5 progenitors. These conclusions are drawn from a broad analysis of effects throughout the limb bud rather than focusing on the cells in question themselves.

The authors have some interesting results and observations. I remain open to the ideas they are suggesting but I do feel strongly that currently the data shown does not support their main conclusions.

*Reviewer \#3:*

The study described the limb phenotype in several Tbx3 conditional and null mutants in careful detail. Most of the conclusions based on whole mount RNA in situs are convincing and new findings. The most novel and surprising finding of the study is that the transcription factor TBX3 is localized to the cilium and interacts with KIF7. HOX proteins have been shown to interact with and inhibit GLI3 in the limb, however cilium localization was not explored. Given that the vast majority of TBX3 protein is in the nucleus ([Figure 6](#fig6){ref-type="fig"}), it seems surprising to me that the tiny amount in the cilium can be detected with IP ([Figure 7E-H](#fig7){ref-type="fig"}). The interaction with GLI3 could be in the nucleus and/or cilium, but KIF7 should not be in the nucleus. To further bolster the most significant claim of the paper, I think that additional experiments are needed. In particular, the specificity of the antibodies must be proven (e.g. using Tbx2 mutant MEFs for the Tbx3 antibody) and ideally some results confirmed using tagged proteins. Tagged GLI3 is available and other proteins could be easily generated. A genetic test would be to determine whether heterozygosity for Kif7 in mice (or knockdown in cells) rescues the defect proposed to be due to increased KIF7. In addition, many of the claims of changes in gene expression based on the RNA-seq data in Tables 2 and 3 do not seem to be significant differences, and some are opposite to what is said in the Results. Thus, the value of the RNA-seq data, is not clear, especially as only two samples were analyzed for each genotype, although I appreciate it is a difficult experiment. Many of the additional points listed below are simple changes that would make the paper more accessible and data more convincing.

[Figure 3A](#fig3){ref-type="fig"}\': The mutant limb looks smaller than the control limb in (A), therefore the domain is expected to be smaller. The text implies the domain is smaller relative to the size of the limb. Which is the case?

\"\[...\]downregulation of posterior genes including Shh, Shh pathway members, Tbx2, Sall1, Dkk1, and Osr1\[...\]\": The decrease is very little (e.g. Sall1 -0.3). More important, why are Grem1, Ptch1 and Gli1 not down in the RNA-seq, which would confirm the data in [Figure 3C, D](#fig3){ref-type="fig"} and address the question of whether the decrease is just due to the limb being smaller?

\"\[...\]up regulation of (AFP, Ttr, Apob, Apoa1, Apoa4, Trf, Ttpa)\[...\](Table 2).": Apob and Ttpa are actually down and the others are barely up in the anterior (Table 2).

Results: \"more single puncta cilia in mutants than controls ([Figure 5E](#fig5){ref-type="fig"} 84% vs 71%, p\<0.001). The levels of Kif7 mRNA\[...\] unaffected\[...\] Tables 2, 3\[...\]\": In Table 3 Kif7 is -0.3, which is greater than many of the changes in expression level claimed elsewhere in the text.

Results: \"The presence of Tbx3 in cilia and response to Hedgehog pathway activation was confirmed with a commercially available anti-Tbx3 antibody and both SAG and Shh stimulation ([Figure 6M, N](#fig6){ref-type="fig"}).\": Tbx mutant fibroblasts should be shown to demonstrate specificity of the antibody.

Tagged proteins should be used to confirm the interactions thought to be detected with commercial antibodies.

[Figure 7C, D](#fig7){ref-type="fig"}: quantification is needed.

Results: \"Consistent with our hypothesis, there was decreased interaction between Gli3FL and Sufu in mutants ([Figure 6E](#fig6){ref-type="fig"}, lane 8\[...\]\": Do the authors mean [Figure 7E](#fig7){ref-type="fig"}? Also, since Gli3 FL and R are reduced, does this experiment say anything?

Discussion: \"Future studies will determine if Tbx3 transcriptional or posttranscriptional activity regulates production of a factor that represses expression or stability of Hand2 mRNA.\": In the posterior limb, wouldn\'t Tbx3 also interfere with processing of Gli2/3 into activators, like in cilia mutants, and this could explain the posterior limb phenotype by the same mechanism as the anterior limb bud?

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"Tbx3 is a Ciliary Protein and Regulates Gli3 Stability to Control Digit Number\" for further consideration at *eLife*. Your article has been favorably evaluated by Janet Rossant (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) There are some remaining concerns about the quality of the biochemical data. Specifically, the composition and the order of loading of the lanes is not the same in [Figure 4B, C](#fig4){ref-type="fig"} and [Figure 7A, B](#fig7){ref-type="fig"}, creating the impression that the shown immunoprecipitations are not from the same experiment. Gli3 and KIF7 blots should be included in [Figure 7C](#fig7){ref-type="fig"}. Most importantly, error bars should be included in the plots showing the quantification of immunoprecipitation results in [Figure 8](#fig8){ref-type="fig"} in order to illustrate that the experiment was performed more than once and the observed differences are significant.

2\) Better discussion should be included to explain why the authors insist that TBX3 does not regulate GLI3 function in the posterior limb, and why they have ignored the highly related protein GLI2. If their hypothesis is correct, one would expect the same might be true for GLI2 since it also binds SuFu and requires cilia for proper processing. Also, if whole embryos reveal the same protein interactions as the anterior limb, why would the posterior limb be different? Gli2/3 double limb mutants could well have a worse posterior limb phenotype than Gli3 null or het mutants. Only a relatively late double conditional mutant of Gli2/3 has been published, and it indicated the posterior phenotype is worse than in single Gli3 mutants. Thus, some of the posterior phenotype in Tbx3 mutants could be due to the altered GLI processing and activity in this tissue, rather than just the decreased Shh expression, especially as Shh heterozygous mutants have normal limbs. Finally, it seems to be an over-interpretation of the data to say that the posterior limb is not dependent on cilia. In cilia mutants' production of both activators and repressors is altered (diminished), but obvious phenotypes are only seen where the balance is greatly skewed. It would be nice to extend the Discussion of your paper to address these points.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"T-box 3 is a Ciliary Protein and Regulates Gli3 Stability to Control Digit Number\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Janet Rossant (Senior editor) and a reviewing editor. The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) The scan of the Western blot shown in [Figure 7C](#fig7){ref-type="fig"} is not publication quality. Please substitute it for a high-resolution scan. Also, please make sure that in all cases where lanes of Western blots have been left out, a clear separator line is present (this currently seems not to be the case in [Figure 7C, 7C\'](#fig7){ref-type="fig"} and [8E](#fig8){ref-type="fig"}).

2\. Please reconsider the title of your paper. \"T-box3 is a ciliary protein and regulates..\" doesn\'t read well. Furthermore, e*Life* encourages the authors to provide brief explanations for the acronyms used in the title and Abstract. For your paper, mentioning that Gli3 is a player in Sonic Hedgehog signaling would be appropriate.

10.7554/eLife.07897.049

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

*Reviewer \#1:*

*1) [Figure 5A](#fig5){ref-type="fig"}: it is very surprising that Tbx3 precipitates with equal efficiency with Tbx3 and Kif7 antibodies. Anti-Kif7 blot must be included here to show the efficiency of Kif7 immunoprecipitation.*

We agree; we have repeated the co-IP a total of 4 times: a different experiment is shown (now in [Figure 4B](#fig4){ref-type="fig"}) than in the original submission and another example is in the new [Figure 7A](#fig7){ref-type="fig"}. The anti-Kif7 blot requested by the reviewer reveals that as predicted, Tbx3 is not as efficiently IP'd by anti-Kif7 antibody as Kif7 itself.

*In the legend, the% of input loaded must be indicated, so that the efficiency of immunoprecipitation can be estimated.*

\% input added to the figures and legends as requested.

*A similar comment applies to [Figure 6O](#fig6){ref-type="fig"}. A Tbx3 blot must be included in this panel, as well as the input lanes, so that the efficiency of immunoprecipitation can be estimated. The loading of IgG in the control lane seems to be lower than in the two other lanes, which makes the value of this control doubtful. It would be preferable, instead of IgG, to use as a negative control antibodies against another protein, which does not bind to Gli3 or Tbx3.*

We have made the additions and changes as requested, and used an additional negative control antibody as suggested by the reviewer. These data are now presented in the current [Figure 7](#fig7){ref-type="fig"}.

*Similar comments also apply to the blots shown in [Figure 7E, G](#fig7){ref-type="fig"} and H. Arl13 blot should be shown in panel E, Kif7 blot in panel G and Sufu blot in panel H. Are the cut blots in panel E (including input lanes) derived from the same or different gels and do they show the same exposures? The observed differences in immunoprecipitation efficiency are not convincing and therefore need to be quantified using three independent experiments for all data shown in [Figure 7](#fig7){ref-type="fig"}.*

Because it requires that a much greater amount of protein be loaded to detect these proteins from non- IP'd material, the blots in panel E were from a different gel to avoid exposure and well distortion issues that arise from the different amounts of protein loaded. The experiments originally presented in [Figure 7](#fig7){ref-type="fig"} have now been repeated a minimum of 3 times and examples are shown in [Figure 8](#fig8){ref-type="fig"} and [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}.

*2) Are there any indications that the interactions of Tbx3 with Kif7 and Gli3 might be direct? For example, do these proteins co-immunoprecipitate when overexpressed in cultured cells?*

We have performed the co-IPs with tagged Kif7 and tagged Gli3 as requested ([Figure 4 C, D](#fig4){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}) in HEK293 cells. We found that Flag-Kif7 and Myc-Tbx3 interact, but Flag-Gli3 and Myc-Tbx3 do not under these conditions.

*3) The specificity of the Tbx3 staining in cilia ([Figure 6](#fig6){ref-type="fig"}) must be confirmed using Tbx3 knockout cells.*

We agree and apologize for not including this critical control in our initial submission. We have now repeated these experiments and used *Tbx3* mutant limb buds ([Figure 5](#fig5){ref-type="fig"}) as well as *Tbx3* mutant MEFs ([Figure 6](#fig6){ref-type="fig"}) and confirmed the specificity of signal in the cilia. Please note that in addition to our custom antibody against the C-terminus of Tbx3, 2 different commercial anti-Tbx3 antibodies detected Tbx3 in cilia ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, Abcam anti-Tbx3 antibody; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, panels C, D SantaCruz A-20 anti-Tbx3 antibody).

*Reviewer \#2:*

*First and foremost, immunostaining for Tbx3 and Arl13b on limb sections is interpreted as showing Tbx3 in limb mesenchymal cilia. Immunostaining of Tbx3 is throughout the entire cell and apparent co-expresssion with Arl13b could simply be explained by overlap in stain. Much higher resolution microscopy imaging that can circumvent these potential artifacts is required. The staining on MEFS do not clarify the issue.*

We agree; please see response to Reviewer 1 above and the new data provided in control and mutant limb buds, including 100X confocal maximum image projections in [Figure 5](#fig5){ref-type="fig"} and the z-stacks provided in Videos 3 and 4.

*It is not clear why the Tbx3 staining pattern is so different in these cells from that shown in A-C.*

We have shown that the staining pattern of Tbx3 is very context/tissue dependent (Frank et al., 2012; Frank et al., 2013, Kumar et al., 2014a *eLife*). In this case, serum starved MEFs are very different than the rapidly proliferating mesenchymal cells in the limb bud. Even within the limb, cells in the AER have a different pattern of Tbx3 staining (mostly cytoplasmic, none in cilia) than those in the mesenchyme (cytoplasmic, nuclear and cilia). In some cell types, such as the dorsal root ganglia, all staining is nuclear. The MEF pattern shown here is very similar to what we demonstrated in MEFs in Kumar et al., 2014a, *eLife*.

*(Other issues such as the legend for panels H-K states 25/33 cilia were Tbx3+. I do not see more than 20 cells or so in this panel further compounding the problem) (It can also be argued that any patterns identified in MEFs may not have relevance to the limb.)*

We apologize for this error; the text was written to describe a larger, lower magnification panel that we subsequently chose to replace with the panel presented. In the revision, we have replaced all of this data with cleaner, higher magnification/better resolution confocal images in [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} that can also be viewed orthogonally and through z-stacks using the free Zen software that we employed to obtain and process the images <http://www.zeiss.com/microscopy/en_de/downloads/zen.html>. In addition to viewing z-stacks through the limb or MEFs, this software also permits the entire stack to be viewed in 3D and orthogonally so that the overlap is visible at the pixel level. We have also employed the image calculator function of this software to objectively quantitate overlap at the pixel level between the Arl13b and Tbx3 signals in control versus mutant. This method is the most sensitive and objective available to us to define true colocalization. It confirms the presence of Tbx3 in cilia and clearly shows Tbx3 immunoreactivity in limb mesenchymal cilia that is virtually absent after Cre recombination in mutants.

*I also could not see a clear effect on KIf7 localization form the panels C in [Figure 5](#fig5){ref-type="fig"}.*

The goal of the panel as shown was to provide the overall picture of a 40X confocal field and to show that there is not an appreciable difference in the number of ciliated limb mesenchymal cells between control and mutant. However, as stated in the legend, the white arrowheads denote the cilia with multiple spots or streak of Kif7 signal. This is quantitated on a much larger scale from many such fields in the bar graph which represents the results from 3 independent reviewers blinded to genotype, scored the Kif7 immunoreactive pattern of the cilia on 20 fields from 3 mutants and 3 controls.

*Table E appears to be an extreme way to show an apparent 8% difference on cilia length (I could not see where these numbers came from).*

We have replaced this Table with more accurate quantitation based on 3D analysis of the cilia, as described in response to Reviewer 1 above; this is in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}.

This section ends with the conclusion that the data show that Tbx3 is present at baseline in cilia and is trafficked to and within cilia in response to hedgehog signaling. Unfortunately, I remain unconvinced of any of this.

*There are similar issues with the data in [Figure 7](#fig7){ref-type="fig"}. Fundamentally I don\'t see clear evidence of co-expression of Tbx3, Gli3 Arl13b although I appreciate that IP data is also included.*

Please see response to Reviewer 1 and extensive new, appropriately controlled data in [Figures 5](#fig5){ref-type="fig"}--[8](#fig8){ref-type="fig"}. We are confident that the reproducible immunofluorescence and IP data we have now provided address the reviewer's doubts.

*The data on effect on GLi3 stability are potentially interesting but perplexing.*

We agree that this is an extremely interesting finding and while discovering the exact mechanism whereby Tbx3 stabilizes Gli3 is beyond the scope of this manuscript, the fact that Tbx3 is in a complex with Kif7 and Sufu which regulates processing and stability of Gli3 provides the first step toward understanding this.

*What is the effect on Gli3 expression in the mutant limbs? It might be expected following reduction of hand2 and Shh expression in the mutant that Gli3 expression would be expanded but the western data would suggest not. Is there more GLi3FLin the MP? It is perhaps surprising that apparently equivalent levels of Gli3R are present in CP and MP.*

As shown by the graph of qPCR results in [Figure 3](#fig3){ref-type="fig"}, and the new in situ images provided there Gli3 mRNA levels are increased, as is expected with decreased Shh activity (Wang et al.,2000). We have now included an early microarrary experiment which also showed upregulation of *Gli3* expression in mutants (new Table 2).

In the posterior mesenchyme, the level of Gli3R is very low compared to anterior and this has been published by numerous groups including (Wang et al.,2000). Although Shh signaling is reduced in *Tbx3* mutants, the westerns all indicated that baseline processing of Gli3FL to Gli3R is intact in mutant posterior mesenchyme.

The Tbx3 cKO is close (but I would not say identical to or a phenocopy of) a Het Gli3 mutant. This is not conveyed in the final schematic which suggests a critical role of Tbx3 in Gli processing and that this in its absence all Gli processing is affected. I would expect a more profound polydactyly if this were the case. The actual \'polydactyly that presents lacks a structure that could be considered a true digit (1H, H\').

The phenotype of Gli3 null heterozygotes or Gli3R deficiency varies depending on genetic background and protein level; and others have also reported polysyndactyly of digit 1 (Wang 2007;Hill et al., 2009; Lopez-Rios et al., 2012;Quinn et al., 2012). The polysyndactylous digit of Tbx3;PrxCre mutants has two phalanges, the primary criteria for digit 1 (thumb) identity. Even in our mutants, although the penetrance is 100%, the severity of the duplication varies. *Tbx3;PrxCre* mutants are Gli3 deficient and not completely lacking Gli3R, thus PPD is the observed (and expected) phenotype. In the Discussion we consider other molecular events occurring in these mutants that may contribute to the phenotype, including overexpression of Zic3.

Our schematic model shows that in the anterior mesenchyme, some Gli3FL remains complexed with Sufu, but most is processed to Gli3R (which is also the case in controls); some of this Gli3R is aberrantly degraded which is what our data show. Our model does *not* indicate that all Gli3 processing is affected. The very low levels of Gli3FL detectable in the mutants are consistent with excess degradation of Gli3FL.

*A further question raised is that if Tbx3 is playing such a critical role in Gli processing/Shh signalling in the anterior is it or why is it not playing a similar role in the posterior. This is not discussed and does not appear to have been studied.*

With due respect to the reviewer, this is not discussed because, unlike other regions of the embryo, Shh signaling in the posterior limb mesenchyme is not dependent on cilia or Gli3R. Mouse mutants of Kif7 and ciliary components have anterior PPD; posterior digits are apparently normal. Our data indicate that Tbx3 regulates ligand-dependent Shh signaling in the posterior mesenchyme by affecting the level of *Hand2* expression upstream of *Shh* and its downstream activator functions. In the anterior, we show strong evidence that Tbx3 regulates ligand-independent pathway function by controlling the stability and processing of Gli3. Gli3 processing requires Kif7, Sufu and intact cilia. Although the interactions and processing may not occur within the cilia proper; the literature supports that they occur in the cytoplasm or centrosome/basal body adjacent to the cilia (reviewed in Ryan and Chiang 2012; Ingham and McMahon 2009; and Wang et al., 2013; Wen et al., 2010, Humke et al., 2005; Tukachinsky et al., 2010).

As the reviewers are aware, the cellular compartments in which different functionally relevant interactions are occurring is an ongoing and highly controversial area in the field for all components of the pathway. Elegant work has been done with tagged proteins and overexpression systems. Despite this, these issues have not yet been resolved, especially for endogenous interactions and functions of Kif7, Sufu or Gli3. What is clear is that even if the functionally relevant interactions are occurring in the cytoplasm adjacent to (or even far) from cilia, processing of Gli3 to Gli3R requires the cilia.

*Some other minor issues from [Figure 1](#fig1){ref-type="fig"} include:*

*1L: I do not see any loss of Sox9 activity in the region indicated with the red arrow head. This domain looks relatively normal to me.*

We agree that *Sox9* expression at E10.5 appears normal however, the morphology of the limb is not at this stage and is variable as is apparent from the images in [Figure 3](#fig3){ref-type="fig"} as well. In [Figure 1L](#fig1){ref-type="fig"}, the red arrow denotes abnormal indentation/lack of posterior tissue while the red bracket highlights extra tissue in the anterior, digit 1 forming region. We have clarified the text on this point.

*I do not see clear evidence of a delay in ossification.*

We have now added a label for the ossification center (oc) to the figures and the legends to clarify. Please consider the images of E15.5 skeletal preps in [Figure 1G, H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} panels K-N. There is no ossification center in the humerus of the mutants, whereas all control and the *Tbx3fl/fl;Fgf8^mcm/mcm^*mutant (which have normal limbs) specimens have a well-defined ossification center.

In the text the authors conclude that this \"reveals a role for Tbx3 in later aspects of Indian hedgehog regulated bone morphogenesis." This has not been investigated to any extent and this type of comments goes far beyond what is actually shown in this paper.

We have removed this statement; it was a hypothesis that we did not test.

Also here the loss of the deltoid tuberosity need not have anything to do a direct effect on bone (cf Blitz, E, 2009).

We agree and did not make this statement.

Comparison of the phenotypes produced using the early acting (RARCre) and later acting (Prx1Cre) appears to show an effect of Tbx3 on the early stages of limb initiation that can be distinguished form later events of limb bud patterning through establishment of Shh in the posterior. A regulatory relationship between Tbx3, Hand2 and Shh has been reported in chick (Rallis, 2005).

We apologize for failing to cite this reference and have included it in the revision.

*Decreased expression of markers detected by RNAseq analysis is interpreted as evidence that fewer cells are undergoing condensation and chondrogenesis in posterior mesenchyme. This would be much better analyzing in a more direct way rather than making inferences from RNA-seq data.*

The lack of digit 5 chondrogenesis is shown in [Figure 1](#fig1){ref-type="fig"} panel N and we have now confirmed the RNA-Seq data of decreased expression of Shh activated targets with qPCR ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}.

*Similarly, 5th digits agenesis is attributed to deceased cell number as opposed to decreased proliferation of digit 5 progenitors. These conclusions are drawn from a broad analysis of effects throughout the limb bud rather than focusing on the cells in question themselves.*

We have now specifically quantified proliferation in the posterior region containing d5 progenitors and added this data to [Figure 3](#fig3){ref-type="fig"}.

*Reviewer \#3: The study described the limb phenotype in several Tbx3 conditional and null mutants in careful detail. Most of the conclusions based on whole mount RNA in situs are convincing and new findings. The most novel and surprising finding of the study is that the transcription factor TBX3 is localized to the cilium and interacts with KIF7. HOX proteins have been shown to interact with and inhibit GLI3 in the limb, however cilium localization was not explored. Given that the vast majority of TBX3 protein is in the nucleus ([Figure 6](#fig6){ref-type="fig"}), it seems surprising to me that the tiny amount in the cilium can be detected with IP ([Figure 7E-H](#fig7){ref-type="fig"}). The interaction with GLI3 could be in the nucleus and/or cilium, but KIF7 should not be in the nucleus.*

We and others have shown (using different antibodies) that Kif7 is present in both the cilia and in scattered punctate regions of unknown composition in the cytoplasm and nucleus ([Figure 4](#fig4){ref-type="fig"}; He et al., 2014) We now also provide a confocal 100X maximum image projection showing this in sectioned limb bud and the z-stack ([Figure 4---figure supplement1](#fig4s1){ref-type="fig"} and Video 2).

The relative amounts of Kif7 in these different compartments have not been determined; most immunofluorescence images (including ours in [Figure 4](#fig4){ref-type="fig"}) highlight the signal in cilia. We have previously demonstrated (and do so again here) that Tbx3 is present in the cytoplasm and the nucleus, and that the relative abundance in these compartments is cell/tissue specific.

We do not claim that the IP'd material only reflects an interaction in the cilia and we think it likely that the relevant interactions between Tbx3, Gli3, Kif7 and Sufu are occurring at the ciliary base or centrosome as has been proposed by Ryan and Chiang and others (reviewed in Ryan and Chiang 2012; Ingham and McMahon 2009; and Wang et al., 2013; Wen et al., 2010, Humke et al., 2005; Tukachinsky et al., 2010). As discussed above, dissecting the cellular compartments in which different functionally relevant interactions has been a major, unsolved challenge in the field. What is clear is that processing of Gli3 to Gli3R requires the cilia. Our schematic specifically avoids indicating any localization for the Kif7/Tbx3/Gli3 complex (beyond anterior mesenchyme) because at this time, we can only hypothesize which subcellular compartment is functionally important. Determining this is clearly beyond the scope of this manuscript.

*To further bolster the most significant claim of the paper, I think that additional experiments are needed. In particular, the specificity of the antibodies must be proven (e.g. using Tbx2 mutant MEFs for the Tbx3 antibody) and ideally some results confirmed using tagged proteins. Tagged GLI3 is available and other proteins could be easily generated.*

We have performed these experiments, provide the data in the revised manuscript, and detailed the changes in response to Reviewers 1 and 2 above.

*A genetic test would be to determine whether heterozygosity for Kif7 in mice (or knockdown in cells) rescues the defect proposed to be due to increased KIF7.*

There is not an increase in the level of Kif7; we detected a change in localization in mutants.

*In addition, many of the claims of changes in gene expression based on the RNA-seq data in Tables 2 and 3 do not seem to be significant differences, and some are opposite to what is said in the Results. Thus, the value of the RNA-seq data, is not clear, especially as only two samples were analyzed for each genotype, although I appreciate it is a difficult experiment. Many of the additional points listed below are simple changes that would make the paper more accessible and data more convincing.*

We apologize for the inconsistencies between the text and the RNA-Seq tables; please see detailed explanations below.

*[Figure 3A](#fig3){ref-type="fig"}\': The mutant limb looks smaller than the control limb in (A), therefore the domain is expected to be smaller. The text implies the domain is smaller relative to the size of the limb. Which is the case?*

The text states "*Hand2* transcripts are reduced in E9.5 and E10.5 *Tbx3;PrxCre* mutantforelimb buds ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}; [Figure 3 A,A](#fig3){ref-type="fig"}')". Based on the in situ images, the domain is both smaller and the intensity of the signal throughout the domain is decreased, which is consistent with fewer transcripts. We now provide qPCR data that support this claim ([Figure 3F](#fig3){ref-type="fig"}). The mutant limbs are not in general smaller at E10.5-11.5; as noted above, the morphology and size varies, as it does among somite-matched wild type embryos, even within the same litter.

*\"\[...\]downregulation of posterior genes including Shh, Shh pathway members, Tbx2, Sall1, Dkk1, and Osr1\[...\]\": The decrease is very little (e.g. Sall1 -0.3).*

To address issues on the RNA-Seq data in general. Comments by both reviewers 2 and 3 led us to go back to the *eLife* website where we found that Tables 2 and 3 were duplicated and incorrectly labeled; the Table we referred to in the text was Table 2 when discussing the *posterior* expression analysis, but the table provided to reviewers labeled as Table 2 contained the *anterior* analysis. We sincerely apologize that the reviewers did not have access to files that were correct, and instead had files that were mislabeled relative to how they were discussed/referred to in the text, and that we failed to catch the error before the manuscript was sent for review.

Since initial submission, we have not had the time to generate sufficient animals to repeat the RNA-Seq experiment, but we have done additional validation of the datasets by qPCR ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). We have now labeled the tables with clear titles, provided methods that precisely describe how the changes contained in the tables were defined. Within the tables, we have labeled the data columns explicitly as mutant or control, and the compartments for the FPKM reads, as well as the pooled sample raw values (2 pools per genotype). We have also included additional data from an early microarray we performed in 2010 which in addition to the phenotypes, initially launched our investigation of the Shh pathway in the posterior and Gli3R in the anterior. This microarray analysis is in the present Table 2; changes that were replicated by the RNA-Seq experiment are highlighted in yellow in this table.

For the comparison of control posterior and mutant posterior (current Table 4), the fold changes in column L are given in log base 2, thus:

*Tbx2* -0.61, (decreased greater than 1.5 fold, statistically significant; also detected by microarray and confirmed by qPCR)

*Dkk1* -0.77, (decreased greater than 1.5 fold, statistically significant; also detected by microarray and confirmed by qPCR)

*Osr1* -0.89, (decreased greater than 1.5 fold, statistically significant; also detected by microarray and confirmed by qPCR)

*Cntfr* -0.93, (decreased greater than 1.5 fold, statistically significant; also detected by microarray and confirmed by qPCR)

On the current Table 4, *Sall1* is not listed because it was not changed more than +/-1.3 fold which was the criteria for inclusion on the table.

*\"\[...\]up regulation of (AFP, Ttr, Apob, Apoa1, Apoa4, Trf, Ttpa)\[...\] (Table 2).": Apob and Ttpa are actually down and the others are barely up in the anterior (Table 2).*

Please note, the manuscript paragraph was describing changes in the *posterior* mesenchyme and Table 2 should have been also *posterior*; as noted above, the reviewer was unfortunately evaluating the anterior analysis and thus it is understandable that the reviewer did not agree with our claims.

In the posterior dataset contained in the present Table 4, log base 2, column L:

Apob +2.7 (increased greater than 4 fold and statistically significant)

AFP +2.1 (increased greater than 4 fold and statistically significant)

Apoa4 +1.7 (increased greater than 2.5 fold and statistically significant)

Ttr +1.4 (increased greater than 2 fold and statistically significant)

Apoa1 +1.3 (increased greater than 2 fold and statistically significant)

Trf +0.6 (increased greater than 1.5 fold and statistically significant)

Ttpa +0.5 (increased greater than 1.5 fold and statistically significant)

However, based on the reviewers' comments and the fact that we do not pursue these changes further, we chose not to make any claims about this set of transcripts in the revised manuscript.

More important, why are Grem1, Ptch1 and Gli1 not down in the RNA-seq, which would confirm the data in [Figure 3C, D](#fig3){ref-type="fig"} and address the question of whether the decrease is just due to the limb being smaller?

The mutant limbs are not in general smaller at E10.5-11.5; as noted above, the morphology and size varies, as it does among somite-matched wild type embryos in the same litter.

We performed thein situs showing decreased expression of these transcripts long before performing the RNA- seq experiment (the entire series of experiments took over 7 years to complete) because the phenotype and wealth of published data led us to consider alterations in Shh pathway activity as at least contributory to the loss of digit 5, and because the 2010 microarray detected the decrements in *Shh, Hand2* and *Gli1* transcripts. We cannot explain the failure of the RNA-Seq experiment to detect these differences. As this and the other reviewers noted, RNA-Seq is a screening test and must be validated for specific genes; in the case of *Shh, Grem1, Ptch1, Ptch2, Gli1, Hand2,* and many others, the in situ and qPCR data are consistent and clear.

Despite the failure of the RNA-Seq to detect some bona fide changes, we do not think that these RNA-Seq data have no value to us or to the field: aside from confirming and expanding on previously published anterior/posterior polarity datasets in the wild type limb (which we have now included in a separate Table 3: Differentially expressed transcripts detected by RNA-Seq of E11 control anterior forelimb versus control posterior forelimb buds), many expression changes detected in the control versus mutant datasets have been validated by multiple methods including in situ hybridization, microarray and qPCR and were also validated for effects on alternative splicing in our 2014 Plos Genetics paper (Kumar et al., 2014b, *eLife*).

*Results: \"more single puncta cilia in mutants than controls ([Figure 5E](#fig5){ref-type="fig"}, 84% vs 71%, p\<0.001). The levels of Kif7 mRNA\[...\] unaffected\[...\] Tables 2, 3 \[...\]\": In Table 3 Kif7 is -0.3, which is greater than many of the changes in expression level claimed elsewhere in the text.*

See notes on the mix-up of the tables above; the original Table 3 reviewed contained the posterior gene expression data. In the current *anterior* analysis (Table 5), Kif7 is not listed on this Table because Kif7 log base 2-fold change is only 0.1042 (1.07 fold, not statistically significant) and only transcripts with changes +/- 1.3 fold (0.38 log base 2) are included on the revised tables.

*Results: \"The presence of Tbx3 in cilia and response to Hedgehog pathway activation was confirmed with a commercially available anti-Tbx3 antibody and both SAG and Shh stimulation ([Figure 6M, N](#fig6){ref-type="fig"}).\": Tbx mutant fibroblasts should be shown to demonstrate specificity of the antibody.*

We agree and have responded as noted in response to other reviewers above. The specificity of our custom antibody has previously been published Frank et al., 2012, Frank et al., 2013 and is also shown in [Figure 1](#fig1){ref-type="fig"} panel E/F and now, specifically relevant to ciliary localization in revised [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}.

*Tagged proteins should be used to confirm the interactions thought to be detected with commercial antibodies.*

These data are now provided for the interactions between Tbx3 and both Kif7 and Gli3. The interactions we detected between Kif7 and Sufu and Gli3 proteins are well established in the literature.

*[Fig7C, D](#fig3){ref-type="fig"}: quantification is needed.*

We have now replicated these experiments and quantitated the changes in interactions using densitometry and the appropriate input controls. These data are in [Figure 8](#fig8){ref-type="fig"} and its supplements.

*Results: \"Consistent with our hypothesis, there was decreased interaction between Gli3FL and Sufu in mutants ([Figure 6E](#fig6){ref-type="fig"}, lane 8\[...\]\": Do the authors mean [Figure 7E](#fig7){ref-type="fig"}? Also, since Gli3 FL and R are reduced, does this experiment say anything?*

We agree that the overall decrease in amount of Gli3 proteins in *Tbx3^△fl/△fl^*mutants makes it difficult to detect any decrement in protein/ protein interactions. We have not only assayed the Sufu/Gli3 interaction in both directions, but quantitated the amount of interaction and compared it to the decrease in protein levels (all in current [Figure 8](#fig8){ref-type="fig"} and its supplements). In general, control embryos have \~ 1.6 fold more Gli3R than *Tbx3^△fl/△fl^* mutants ([Figure 8A, A'](#fig8){ref-type="fig"} lanes 1-4, and [Figure 8---figure supplement 2A and B](#fig8s2){ref-type="fig"}). However, the ratio of Gli3R interacting with Sufu in controls ranges from 4.3 to 9.5 fold higher than in mutants ([Figure 8---figure supplement 2A-B](#fig8s2){ref-type="fig"}'). The interaction with Gli3FL is harder to assess reliably/quantitatively because of variable transfer efficiency due to high molecular weight. In the experiment shown in [Figure 8A](#fig8){ref-type="fig"}, the ratio of Gli3FL in controls to mutants is 1.6-1.7, while the ratio of that IPd with Sufu is 4.6 fold greater in controls. When assaying for Sufu that coIPs with Gli3, the change is not as dramatic because it reflects the Sufu that IPs with all GLi3 species ([Figure 8B](#fig8){ref-type="fig"}).

*Discussion: \"Future studies will determine if Tbx3 transcriptional or posttranscriptional activity regulates production of a factor that represses expression or stability of Hand2 mRNA.\": In the posterior limb, wouldn\'t Tbx3 also interfere with processing of Gli2/3 into activators, like in cilia mutants, and this could explain the posterior limb phenotype by the same mechanism as the anterior limb bud?*

As discussed in detail above, Shh signaling in the posterior limb bud is [not]{.ul} cilia dependent; no ciliary mutants described thus far have posterior limb defects. Cilia mutants fail to process Gli3FL into Gli3R but as discussed above and in the manuscript, cilia phenotypes affect anterior digit number. Our data do not reveal any decrease in GliFL in the posterior, Shh responsive compartment.

\[Editors' note: the author responses to the re-review follow.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below: 1) There are some remaining concerns about the quality of the biochemical data. Specifically, the composition and the order of loading of the lanes is not the same in [Figure 4B, C](#fig4){ref-type="fig"} and [Figure 7A, B](#fig7){ref-type="fig"}, creating the impression that the shown immunoprecipitations are not from the same experiment. Gli3 and KIF7 blots should be included in [Figure 7C](#fig7){ref-type="fig"}.*

We responded with this query on Jan. 26:

"We agree that it is not ideal that the order of the lanes is not consistent; nonetheless, the IPs were from the same experiment/limb bud lysates. These experiments were repeated at the request of the reviewer from the first submission. Since these IPs require literally hundreds of limb buds, and the results shown in the revision reproduce those originally presented, repeating them for the sake of changing the order of the lanes seems excessively burdensome and time/embryo consuming given that the conclusion is unchanged."

We received this response from *eLife*:

*1) [Figure 4B, C](#fig4){ref-type="fig"} and [Figure 7A, B](#fig7){ref-type="fig"}: Repeating the experiment just to present a consistent order of the lanes is indeed not necessary in this case since the material is difficult to obtain. The authors should state in the main text of the paper (if this is correct) that the lanes shown in these gels are from the same immunoprecipitations.*

We apologize that the order of the lanes is not consistent; the IPs were from the same experiment and that is now stated in the text.

Control blots for Gli3 and KIf7 from the same experiment should be included in [Figure 7C](#fig7){ref-type="fig"}.

Now provided.

*Most importantly, error bars should be included in the plots showing the quantification of immunoprecipitation results in [Figure 8](#fig8){ref-type="fig"} in order to illustrate that the experiment was performed more than once and the observed differences are significant.*

We sent this query on Jan. 26:

"To clarify, [Figure 8](#fig8){ref-type="fig"} shows analysis of each protein-protein interaction performed once in each direction. The quantitation in the accompanying bar graph is for the blot shown and that is why the bar graphs do not have error bars. The repeat experiments showing that the altered interactions are reproducible, and their quantitations, are in [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}.

When considering these blots, it is important to realize that the IP and transfer efficiency do unavoidably vary from experiment to experiment, making it impossible to combine raw densitometry intensity data from all experiments to obtain the type of statistical analysis the reviewer is requesting. Furthermore, we think that the key point is that the changes in interactions in mutants are reproducible from experiment to experiment and when assayed in both directions.

As the reviewers are aware, it took 7 months to obtain sufficient numbers of embryos to provide the repeat experiments requested in the first review. We appreciate your reconsideration and additional clarification as to what it required for acceptance of our final submission."

We received this response from *eLife*:

*"Quantification of immunoprecipitation results in [Figure 8](#fig8){ref-type="fig"}: It is obvious that to draw any conclusions about protein quantities on Western blots, each experiment should be performed at least twice. It is also obvious that the raw densitometry data cannot be compared between different experiments. However, band intensity ratios, which are currently presented per experiment, should be easy to combine and average between two or more experiments/samples, generating error bars. The authors should also label these plots appropriately (for example, instead of \"ratio wt to mutant, lanes 1:2\" use a label \"Gli3FL, anti-Gli3-IP, ratio wt to mutant\", etc.). Basically, instead of leaving the job of comparing different experiments to the reader, the authors should combine the quantitative outcome of their repeated experiments in one plot and include it in the main figures of the paper* \".

We have now remade [Figure 8](#fig8){ref-type="fig"} and supplements in accordance with these requests. We have separated [Figure 8](#fig8){ref-type="fig"} into sections entitled: Gli3/Sufu Interactions; Gli3/Kif7 Interactions; Kif7/Sufu Interactions

Within each of these sections, the upper blots are representative IP experiments that were repeated 3 times. Adjacent to these blots are bar graphs with the averaged band intensities and standard error of the mean. The lower blots in each section are the complementary IP/western performed in the "other direction"; these complementary experiments were done once, so the bar graphs only show the ratio of band intensities between control and mutant for that experiment.

So, for each interaction, we not only performed replicate experiments (some of which are presented in [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}), but also the complementary experiments. We hope the reviewers agree that this is a rigorous analysis for a methodology that is difficult to quantitate.

"*Please note that ratio of two bands cannot be negative (because if one positive value is divided by another positive value, the outcome is positive), so the values showing an increase in the mutant should be presented differently".*

Thank you for the correction. We have remedied this in [Figure 8](#fig8){ref-type="fig"} and [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}.

*2) Better discussion should be included to explain why the authors insist that TBX3 does not regulate GLI3 function in the posterior limb, and why they have ignored the highly related protein GLI2. If their hypothesis is correct, one would expect the same might be true for GLI2 since it also binds SuFu and requires cilia for proper processing. Also, if whole embryos reveal the same protein interactions as the anterior limb, why would the posterior limb be different? Gli2/3 double limb mutants could well have a worse posterior limb phenotype than Gli3 null or het mutants. Only a relatively late double conditional mutant of Gli2/3 has been published, and it indicated the posterior phenotype is worse than in single Gli3 mutants. Thus, some of the posterior phenotype in Tbx3 mutants could be due to the altered GLI processing and activity in this tissue, rather than just the decreased Shh expression, especially as Shh heterozygous mutants have normal limbs.*

We agree, and have considered and investigated this further. While *ShH^+^*/- mutants do not have an abnormal digit phenotype, and they have half as much *Shh* mRNA in their limb buds, the amount of protein is normal (Brian Harfe, personal communication/manuscript in revision) revealing a compensatory mechanism at the translational or post-translational level. Sanz-Ezquerro and Tickle (2000) proposed a compensatory, buffering system to stabilize polarizing activity in chick limb stating: "A buffering system can account for several regulative features of polarising region signalling. It can explain why limbs with normal patterns develop after application of extra Shh polarising region cells (Tickle et al., 1975), Shh expressing cells (Riddle et al., 1993) or Shh beads (Yang et al.,1997) to the posterior margin of chick buds, and why normal patterned limbs also develop after most, but not all, of the polarising region is removed (Fallon and Crosby, 1975; Pagan et al., 1996)."

Additionally, the *ShH^+^*/- genotype is sensitized to other mutations. For example, Zeller's lab showed that rescued digits in Grem1-/-;Bmp4+/- are more sensitive to reduced Shh level (Benazet et al., 2009) and Hui\'s lab showed that Irx3/5 KO (excess HH activity) is improved by Shh dosage reduction. In addition, the Wnt7a mutant (Parr and McMahon, 1995), which affects Shh activation, has loss of digit 5. Mackem's group re-evaluated the Wnt7a mutant (Zhu and Mackem, 2009), and found delayed onset and decreased level of *Shh* expression -- which is consistent with our results.

In consideration of this information and to address the reviewers'suggestions, we have modified the model presented in [Figure 9](#fig9){ref-type="fig"} and added the following paragraphs to the relevant sections of the Discussion.

For the section discussing posterior phenotype and mechanisms:

"Digit 5 formation is exquisitely sensitive to Shh activity and Grem1 (Harfe et al., 2004; Scherz et al., 2007; Zhu and Mackem, 2011; Zhu et al., 2008), so the altered expression of these genes in posterior mutant mesenchyme helps explain loss of this digit. \[...\] Nonetheless, it is possible that decreased Shh signaling in the posterior of *Tbx3;PrxCre* mutant limb buds creates changes in Gli3 levels/ratios below our ability to detect. If so, decreased Shh activity would be predicted to increase Gli3R, decreasing digit number."

For the section discussing anterior phenotype and mechanisms we have added:

"Loss of Tbx3 could also influence stability and processing of Gli2. The anterior PPD phenotype of *Gli3* heterozygotes is slightly more severe in a *Gli2* null background (Bowers et al., 2012; Mo et al., 1997). \[...\] This is consistent with our findings that Tbx3 affects anterior digit number by regulating Gli3 repressor stability in the anterior mesenchyme."

Finally, it seems to be an over-interpretation of the data to say that the posterior limb is not dependent on cilia. In cilia mutants' production of both activators and repressors is altered (diminished), but obvious phenotypes are only seen where the balance is greatly skewed. It would be nice to extend the Discussion of your paper to address these points.

We agree; in the manuscript, we discuss what is known with regard to ciliary function and limb phenotypes but do not exclude the possibility of posterior functions yet to be determined.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below: 1) The scan of the Western blot shown in [Figure 7C](#fig7){ref-type="fig"} is not publication quality. Please substitute it for a high-resolution scan.*

We have replaced the image in 7C with that exported at 600 dπ from the scanner; we have shown the original image without any alterations to lane order or intensity. Because of the magnification at which the image was originally taken, the Biorad scanner gives a pixelated quality to the over exposed IgG bands and unfortunately, this is the lowest exposure we have of this experiment. We have provided additional experiments showing the Gli3/Tbx3 interaction in the new [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.

*Also, please make sure that in all cases where lanes of Western blots have been left out, a clear separator line is present (this currently seems not to be the case in [Figure 7C, 7C\'](#fig7){ref-type="fig"} and [8E](#fig8){ref-type="fig"}).*

For [Figure 7C](#fig7){ref-type="fig"}, the new image shown was exported at 600 dπ from the scanner; we have shown the original image without any alterations to lane order or intensity, thus there are no lane rearrangements requiring separator lines. We have added more obvious separators to [Figures 7C'](#fig7){ref-type="fig"}and [7C"](#fig7){ref-type="fig"} and presented these blots with lane order consistent with that of Panel 7C. We have added the requested separator to [Figure 8E](#fig8){ref-type="fig"}.

2\. Please reconsider the title of your paper. \"T-box3 is a ciliary protein and regulates..\" doesn\'t read well. Furthermore, eLife encourages the authors to provide brief explanations for the acronyms used in the title and Abstract. For your paper, mentioning that Gli3 is a player in Sonic Hedgehog signaling would be appropriate.

We have revised the title to: "T-box 3 is a Ciliary Protein and Regulates Stability of the Gli3 transcription factor to Control Digit Number". We think that including Sonic Hedgehog signaling in the title is too cumbersome and also, inaccurate because its function in the anterior is Shh independent, as stated in the Abstract. We are open to suggestions if the title is still not satisfactory.

We have revised the Abstract as requested to include additional reference to Gli3 as a transcriptional effector in the Hedgehog pathway:

"Crucial roles for T-box3 in development are evident by severe limb malformations and other birth defects caused by T-box3 mutations in humans. \[...\] Remarkably, T-box3 is present in primary cilia where it colocalizes with Gli3. T-box3 interacts with Kif7 and is required for normal stoichiometry and function of a Kif7/Sufu complex that regulates Gli3 stability and processing. Thus T-box3 controls digit number upstream of Shh-dependent (posterior mesenchyme) and Shh-independent, cilium-based (anterior mesenchyme) Hedgehog pathway function."

[^1]: These authors contributed equally to this work.
